Discovery of novel mechanisms of centrosome amplification and their therapeutic value in cancer by Almeida, Bernardo Lucas Carvalho Pereira de
Bernardo Lucas Carvalho Pereira de Almeida 
Discovery of novel mechanisms of centrosome amplification 
and their therapeutic value in cancer 
UNIVERSIDADE DO ALGARVE 
Departamento de Ciências Biomédicas e Medicina 
2017 

i 
Bernardo Lucas Carvalho Pereira de Almeida 
Discovery of novel mechanisms of centrosome amplification 
and their therapeutic value in cancer 
Master in Oncobiology – Molecular Mechanisms of Cancer 
This work was done under the supervision of: 
Nuno Barbosa Morais, Ph.D 
Ana Teresa Maia, Ph.D 
UNIVERSIDADE DO ALGARVE 
Departamento de Ciências Biomédicas e Medicina 
2017 
ii 
iii 
Discovery of novel mechanisms of centrosome amplification 
and their therapeutic value in cancer 
Declaração de autoria de trabalho 
Declaro ser o autor deste trabalho, que é original e inédito. Autores e trabalhos 
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ABSTRACT 
Genomic instability is a hallmark of cancer cells that generates the genetic diversity that 
makes possible the acquisition of all the other hallmarks. Thus, the maintenance of genome 
stability is critical for proper cell function. Centrosomes, the major microtubule-organising 
centres of animal cells, are the main subcellular organelles implicated in the maintenance of 
genome stability. It is therefore not surprising that centrosome amplification (CA) – the 
presence of more than one centrosome in a cell – is a common feature in cancer. Recent work 
from the Bettencourt-Dias Lab has identified a new recurrent feature of cancer cells: centriole 
over-elongation (COE), which also promotes CA. Those abnormalities are specific features of 
cancer cells and hence appealing targets in cancer therapy. However, their origins and 
therapeutic value remain poorly understood, preventing their use in the clinic. 
We have screened the NCI-60 panel of human cancer cell lines for centriole number and 
individual length to test their frequency and interdependence. We have thereby also generated 
a metric capturing each abnormality level per cell line that we then correlated with the publicly 
available molecular (particularly transcriptomic and proteomic) and drug-sensitivity 
quantitative profiles for that panel. 
Our work showed lower frequency of COE compared to CA and lung and skin as the 
primary cancer tissues with higher centriole length heterogeneity. However, the two features 
are not independent, with overly-longer centrioles being more common in cells with CA. Our 
single-cell analyses have also suggested that cells apparently do not control their overall 
centriolar mass when the centriole number increases. Moreover, cancer cell lines with longer 
centrioles proliferated slower due to an accumulation of cells in G1 phase, suggesting that 
centriole length defects could lead to a cell cycle delay in G1. In addition, our original genome-
wide approach highlighted putative mechanisms associated with both abnormalities in cancer, 
such as the PRKACA kinase promoting COE and the proteasome protecting cells from CA. 
Correlation with drug activity have both associated CA with higher sensitivity to compound 
activity and also identified some compounds as potential therapeutic options to selectively 
target cells with higher incidence of centriole abnormalities. 
This work provides the first single-centriole-level portrait of centriole abnormalities in 
cancer and contributes to the understanding of their molecular origins, namely by revealing 
novel molecular mechanisms in cell cycle biology. Given the cancer-specificity of these 
abnormalities, the identified compounds will inspire the development of clinical applications 
based on selectively targeting these Achilles’ heels of cancer cells. 
Keywords: cancer; genomic instability; NCI-60 panel; centrosome amplification; centriole 
over-elongation; targeted therapies. 
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RESUMO 
O cancro é um grupo de doenças complexas e heterogéneas caracterizadas por uma 
proliferação celular descontrolada. Uma propriedade intrínseca das células de cancro é a 
instabilidade genómica, cuja presença origina a diversidade genética que lhes possibilita a 
aquisição de outras propriedades cancerígenas. Deste modo, o controlo da estabilidade 
genómica é fundamental para um normal funcionamento celular. 
Os centrossomas, constituídos por dois centríolos, são centros organizadores de 
microtúbulos nas células animais e os principais organelos celulares envolvidos na manutenção 
da estabilidade genómica. Não é, portanto, surpreendente que a amplificação centrossomal 
(CA) – a presença de mais do que um centrossoma numa célula – seja uma característica 
comum em cancro. De fato, a CA está descrita como o principal mecanismo subjacente ao 
desenvolvimento de mitoses multipolares, e consequente instabilidade genómica, e foi 
recentemente observada como sendo suficiente para provocar tumorigénese. Trabalho recente 
do grupo liderado pela investigadora Dr. Mónica Bettencourt-Dias identificou uma nova 
característica frequente em células cancerígenas: sobre-elongação centriolar (COE), a qual 
também promove CA. Ambas as anormalidades centriolares são específicas das células 
cancerígenas e, portanto, alvos promissores para o tratamento do cancro. No entanto, as suas 
origens e valor terapêutico continuam por explorar, impedindo o seu uso na prática clínica. 
Para investigar estas questões, o grupo da Dr. Mónica Bettencourt-Dias quantificou o 
número e comprimento dos centríolos por célula num painel de 60 linhas celulares derivadas 
de diferentes cancros humanos (painel NCI-60, de acesso público). Este painel de linhas 
celulares foi, num estudo prévio, testado quanto à sua sensibilidade a drogas e extensamente 
caracterizado aos níveis genómico, transcriptómico e proteómico, entre outros. A integração 
dos dados resultantes de ambos os estudos proporciona um recurso sem precedentes para 
estudar anormalidades centriolares em cancro. 
O presente projeto de tese teve como principais objetivos 1) caracterizar as anormalidades 
centriolares ao longo do painel NCI-60, 2) explorar as origens moleculares de tais 
anormalidades e 3) identificar novos compostos que tenham como alvo a CA. 
Com vista a alcançar os objetivos propostos, começou-se por testar a frequência e 
interdependência de CA e COE no painel, tendo depois a sua frequência sido utilizada para 
gerar métricas que caracterizassem o grau de cada anormalidade por linha celular. Estas 
métricas foram depois correlacionadas com os diferentes perfis moleculares (nomeadamente 
transcriptómico e proteómico) e de sensibilidade às drogas disponíveis para aquele painel. 
xii 
As nossas análises no painel NCI-60 confirmaram CA e COE como características 
prevalentes em linhas celulares de cancro associadas a diferentes tecidos de origem. Foi 
observada uma maior frequência de anormalidades no número de centríolos, comparativamente 
com anormalidades no seu comprimento, tendo CA sido também associada com os subtipos 
mais agressivos de cancro da mama e do cólon. Aproveitando a resolução ao nível de centríolos 
individuais, observou-se grande variabilidade tanto no número como no comprimento de 
centríolos por célula entre os diferentes tecidos de cancro, representados neste estudo por linhas 
celulares deles derivadas. Para além disso, verificou-se uma elevada heterogeneidade no 
comprimento centriolar entre linhas celulares com o mesmo tecido de origem, particularmente, 
com origem no pulmão e na pele. 
A associação entre COE e CA foi validada no painel NCI-60 tanto ao nível de população 
de células, onde ambas as anormalidades estavam positivamente correlacionadas, como ao 
nível de centríolos individuais, onde foi observada uma maior proporção de centríolos longos 
em células com CA. Comparações entre a distribuição observada do número de centríolos 
longos em cada célula e a esperada, caso COE fosse um evento estocástico, revelaram que a 
COE é dependente do estado fisiológico da célula. Ademais, análises de células individuais de 
cancro revelaram que estas não controlam a sua massa centriolar quando o número de 
centríolos aumenta. 
A associação entre as anormalidades centriolares e a proliferação celular foi avaliada 
usando o tempo de duplicação da população de células e a proporção de células em cada fase 
do ciclo celular. Linhas celulares com centríolos longos apresentaram uma menor taxa de 
proliferação devido a uma acumulação de células na fase G1, sugerindo que a COE pode levar 
a um atraso no ciclo celular em G1. 
Relativamente aos mecanismos moleculares associados com a COE, análises de 
correlação entre a prevalência desta característica e a expressão, aos níveis transcricional e 
proteico, de virtualmente todos os genes presentes no genoma, juntamente com resultados de 
um estudo independente de potenciais reguladores do comprimento centriolar, revelaram a 
proteína PRKACA como potencial promotora de COE em cancro. Esta proteína codifica uma 
subunidade catalítica da quinase PKA, cuja localização celular é maioritariamente ao nível do 
centrossoma. Elevados níveis da proteína PKA foram previamente associados com 
comprimento elevado do cílio primário, mas não é conhecida nenhuma associação entre esta 
quinase e o comprimento dos centríolos, pelo que a associação encontrada em ambos os estudos 
necessita de validação experimental. Para além disso, as análises de correlação mencionadas 
acima identificaram vias de sinalização de interação com a matriz extracelular positivamente 
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associadas com COE. Em sentido oposto, a sub-expressão de genes envolvidos nos 
mecanismos de reparação do DNA foi associada com um aumento do comprimento dos 
centríolos.  
Os mecanismos moleculares de CA em cancro foram também investigados através de 
análises de correlação entre a frequência desta característica e a expressão génica, das quais o 
proteassoma despontou como o principal candidato a explicar os níveis de CA observados nas 
linhas celulares do painel NCI-60: diversos genes que codificam para os diferentes 
componentes do proteassoma estavam negativamente associados com o número de centríolos 
por célula. Em particular, a proteína PSMD1, responsável pelo reconhecimento e ligação aos 
substratos, foi a que apresentou uma associação negativa mais forte. Estudos anteriores 
indicaram que o proteassoma está maioritariamente localizado no centrossoma, sendo 
responsável por controlar os níveis de várias proteínas centrossomais, incluindo as principais 
participantes na duplicação centriolar. Para além disso, estudos em Drosophila demonstraram 
que inibição do proteassoma induz CA. As observações no NCI-60 são concordantes com esta 
hipótese, na qual o proteassoma é proposto como um mecanismo de proteção das células para 
com a CA. De realçar, no entanto, que esta é a primeira evidência deste mecanismo em contexto 
de cancro, sugerindo um novo mecanismo molecular para a origem da CA. 
Para além dos perfis moleculares das linhas celulares do painel NCI-60, estão disponíveis 
os seus perfis quantitativos de sensibilidade a cerca de 50,000 compostos. Estes perfis foram 
primeiramente utilizados com vista a investigar se a CA está globalmente associada a maior 
sensibilidade ou resistência a drogas. De fato, foi observada uma forte associação entre CA e 
uma maior sensibilidade às drogas, realçando o seu potencial como futuro alvo terapêutico. De 
seguida, análises de correlação entre a sensibilidade a estes compostos e os níveis de CA, bem 
como os de expressão do gene PLK4, gene que codifica para a principal proteína reguladora da 
duplicação centriolar, identificaram alguns compostos como potenciais opções terapêuticas 
para eliminar seletivamente as células com elevados níveis de CA e PLK4, respetivamente. 
Este estudo apresenta a primeira caracterização, ao nível de centríolos individuais, de 
anormalidades centriolares em cancro e contribui para uma melhor compreensão das suas 
origens moleculares, revelando concomitantemente novos mecanismos biológicos envolvidos 
no ciclo celular. Visto que aquelas anormalidades são específicas das células de cancro, os 
compostos identificados neste projeto irão inspirar o desenvolvimento de novas terapias 
direcionadas em oncologia. 
 
Palavras-chave: cancro; instabilidade genómica; painel NCI-60; amplificação centrossomal; 
sobre-elongação centriolar; terapias direcionadas. 
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CHAPTER 1 – INTRODUCTION 
1.1 Cancer 
Cancer is a group of complex and heterogeneous diseases characterized by uncontrolled 
proliferation of cells that can invade surrounding tissues and spread to distant organs, i.e. 
metastasize (Strachan and Read, 1996). This cellular condition is mainly generated by the loss 
of normal growth control that results from the accumulation of genetic alterations over time 
with, in some cases, also an inherited predisposition. Thus, cancer can be seen as a disease of 
the genome (Garraway and Lander, 2013; Macconaill and Garraway, 2015). 
All cancers begin with defective cells. Normal cells have genes that directly or indirectly 
control cell proliferation. However, sometimes a change happens in the DNA sequence of those 
genes – called a genetic alteration – and abnormal cells lose the ability to control their 
proliferation. Mutations, defined as permanent alterations in the DNA sequence, are the most 
common alterations observed in cancer and they can arise by chance in proliferating cells, be 
it caused by the natural processes in our cells or by environmental perturbations such as tobacco 
smoke or UV radiation (Nowak and Waclaw, 2017; Tomasetti and Vogelstein, 2015). These 
mutations that occur at certain point during a person’s life and are present only in certain cells 
are called somatic mutations (Campbell, 2016; Greenman et al., 2007). Some people can also 
inherit alterations (hereditary mutations) in particular genes that confer higher susceptibility to 
develop cancer (Nielsen et al., 2016; Rahman, 2014). Other common genetic alterations are 
chromosomal translocations, gene amplifications and gene deletions (Vogelstein et al., 2013). 
Cancer-related genetic alterations occur mainly in four types of genes: oncogenes and 
tumour suppressor genes (genes that promote or inhibit cell division, respectively), DNA repair 
genes (that repair other damaged genes) and self-destruction genes (that promote cell death) 
(Garraway and Lander, 2013; Macconaill and Garraway, 2015). 
1.1.1 Models of cancer development 
Cancer starts with mutations in one cell or a small group of cells. If these changes confer 
proliferative advantage, the mutant clones will tend to overcome normal cells and take over the 
organism (Garraway and Lander, 2013; Greaves and Maley, 2012). Over time, sequential 
acquisition of mutations will generate sub-clone diversity, consequent cancer heterogeneity, 
and select the most capable/aggressive cancer cells. Thus, cancer can be seen as a natural 
evolutionary process (Nowell, 1976), a disease of Darwinian clonal evolution involving 
dynamic changes in the genome (Merlo et al., 2006, Figure 1.1). 
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Figure 1.1 Clonal evolution in cancer. a) Different mutations create genetically distinct subclones 
(represented with different colours) which will compete when faced with some selective pressure 
(vertical lines), e.g. therapy (Tx). Selective pressure allows some subclones to expand while others 
become extinct and/or quiescent, selecting for the most aggressive cancer cells in each particular 
environment. Ecosystems 1–4 (boxes) represent the different tissue ecosystems and consequently 
different kinds of selective pressures, selecting for different subclones - the most capable for each 
ecosystem. CIS, carcinoma in situ. b) Branching evolutionary tree of speciation from Darwin’s 1837 
notebook (adapted from Greaves and Maley, 2012). 
This clonal evolution model was proposed by Peter Nowell over 40 years ago (Nowell, 
1976) and attempted to explain the origin of cancer and its heterogeneity - one of the greatest 
puzzles for cancer researchers. Although this evolutionary model is considered a bona fide 
scientific theory, surviving to 40 years of empirical observation and testing (Greaves and 
Maley, 2012), a new theory has emerged in the last years – the cancer stem cell (CSC) model 
(Kreso and Dick, 2014). 
The CSC hypothesis was developed as a result of transplantation experiments with 
leukemic cells and proposes that cancer is clonally derived by small subpopulations of CSCs 
(Dick, 2008; Reya et al., 2001). The results of these experiments showed that mice were 
developing leukaemia only when they were injected with a specific group of cells – the 
leukemic stem cells. The same was already observed in solid cancers, with the first 
identification of CSCs achieved in human breast cancer over ten years ago (Al-Hajj et al., 
2003). The CSC model suggests that many cancers may be hierarchically organized like normal 
tissues, where stem cells differentiate into diverse progeny with limited proliferative potential. 
Thus, to characterize and eliminate cancers that follow this model, it is necessary to focus on 
the small subpopulations of tumourigenic cells (Shackleton et al., 2009). 
However, these models are not mutually exclusive, as CSCs and their progeny are also 
expected to evolve by clonal evolution. The existence of CSCs and the inherently Darwinian 
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character of cancer seem to be the main causes of therapeutic failure but perhaps also hold the 
key to more effective cancer control (Kreso and Dick, 2014; Shackleton et al., 2009) 
1.1.1.1 Driver and passenger mutations 
All cancers arise as a result of hereditary or somatically acquired mutations, but that does 
not mean that all changes present in a cancer genome are involved in the oncogenic process. 
Genetic mutations occur by chance with respect to adaptation but we can distinguish between 
driver and passenger mutations. A driver mutation is causally implicated in cancer 
development - it confers growth advantage to cancer cells, is positively selected along cancer 
lineages and, therefore, is usually observed in a greater proportion of cancer samples than what 
would be expected by chance. Passenger mutations are the ones that occur along the way but 
do not confer growth advantage, therefore not contributing to cancer development. These 
somatic mutations without functional consequences are the majority of alterations (Lawrence 
et al., 2013; Stratton et al., 2009). 
1.1.2 Epidemiology 
Cancer is one of the leading causes of morbidity and mortality worldwide, with 14.1 
million new cancer cases, 8.2 million cancer deaths and 32.5 million people living with cancer 
(within 5 years of diagnosis) in 2012 (Ferlay et al., 2015). In Portugal, 49,174 people were 
diagnosed and 24,112 died from cancer, also in 2012 (Ferlay et al., 2013a). 
Currently, cancer is still the second leading cause of death worldwide (Global Burden of 
Disease Cancer Collaboration, 2015) but it is predicted to overtake cardiovascular diseases 
(CVD) in the early future (Townsend et al., 2016). Indeed, this is already happening in Europe, 
with cancer being responsible for more deaths than CVD in 12 European countries (Townsend 
et al., 2016). Moreover, the sooner the overtaking happened, the higher is the current ratio of 
cancer to CVD deaths, suggesting this ratio keeps increasing even in those countries 
(Townsend et al., 2016; Figure 1.2). 
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Figure 1.2 Association between the year where cancer overtook CVD as the leading cause of death 
and the current ratio of cancer to CVD deaths, by sex and European country. Data for countries 
without a gender symbol are for men only (adapted from Townsend et al., 2016). 
The incidence of cancer is also a growing problem across the world, being expected to 
increase to 24 million new cancer cases/year by 2035 (Ferlay et al., 2013b). For instance, recent 
estimates from Cancer Research UK suggest that one in two British adults born after 1960 will 
develop cancer in their lifetime, with tendency to rise in future generations due to increasing 
life expectancy (Ahmad et al., 2015). What is behind this association? 
1.1.2.1 Cancer: a disease of older people 
The human body experiences about 10,000 trillion cell divisions in a lifetime, each of 
them with very small chance of error in DNA replication and segregation and consequent 
genetic/genomic alteration (Quammen, 2008). The development of cancer is a multistep 
process that usually requires two to eight mutational driver events to happen in the same cell 
(Vogelstein et al., 2013), which is very unlikely. However, with increasing age people have 
more time to acquire these genomic alterations and therefore the small chances add up, making 
cancer a disease of older people (Cancer Research UK; Figure 1.3). Indeed in the UK, between 
2012 and 2014, 50% of all diagnosed cancer cases were in people aged 70 and over (Cancer 
Research UK), whereas in the United States 86% were diagnosed in people 50 years of age or 
older in 2016 (American Cancer Society, 2016), confirming age as the greatest risk factor for 
cancer development. 
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Figure 1.3 Cancer incidence increases with age. Average number of new cases per year and age-
specific incidence rates per 100,000 inhabitants in the UK. Data for all cancers, excluding Non-
Melanoma Skin Cancer, from 2012 to 2014 (adapted from Cancer Research UK). 
1.1.2.2 Different types of cancer 
Cancer can result from abnormal proliferation of any of the different types of human 
cells, so, in theory, there are over 200 different types of cancer in humans, with very different 
behaviour and response to treatment (Cooper, 2000). Indeed, the incidence and mortality varies 
a lot across cancers in different tissues. 
The most common cancers arise from epithelial tissue cells and are called carcinomas. 
The tissues with higher incidence in 2012, according to GLOBOCAN 2012, were lung (1.82 
million), breast (1.67 million), and colorectal (1.36 million). The most common causes of 
cancer death were lung (1.6 million), liver (745.000), and stomach cancer (723.000) (Ferlay et 
al., 2015). 
Cancer incidence also varies between genders. The most common types of cancer in men 
are lung, prostate and colorectal cancer, while breast, colorectal, and cervix cancer are the most 
common among women (Ferlay et al., 2015). 
1.1.3 Hallmarks of cancer 
The transformation from a normal cell into an abnormal one, and therefore into cancer, 
is a complex and multistage process. The initial mass of abnormal cells is called a tumour, but 
not all tumours develop into a malignant/invasive one – denominated cancer. In 2000, Douglas 
Hanahan and Robert Weinberg published a seminal review that has influenced the study of 
cancer and the development of new therapeutics in oncology. They have proposed six 
fundamental properties (basic capabilities) that are acquired during the multistep development 
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of human tumours (tumourigenesis) and which are required for the development of cancer. 
These “hallmarks of cancer” include (Hanahan and Weinberg, 2000): 
1. Sustaining proliferative signalling;
2. Evading growth suppressors;
3. Activating invasion and metastasis;
4. Enabling replicative immortality;
5. Inducing angiogenesis;
6. Resisting cell death.
However, care must be taken with the definition of a hallmark of cancer. A comment 
article in Nature Reviews Cancer in 2010 (Lazebnik, 2010) pointed out that five of the 
hallmarks were also characteristic of benign tumours, not classified as cancer because they do 
not metastasize to other parts of the body, and the only hallmark exclusive of cancer was the 
ability to invade and metastasize. Why were those five features considered to be in the same 
“league” as tissue invasion and metastasis? Well, the authors suggest that a potential and 
worrying explanation could be that “in many publications, including the article under 
discussion, the terms tumour and cancer are used interchangeably, perhaps because in the 
minds of many basic scientists these terms now mean the same thing” (Lazebnik, 2010). 
In an update published in 2011 (“Hallmarks of cancer: the next generation”), Hanahan 
and Weinberg have revisited, refined, and extended this concept of cancer hallmarks proposing 
two new emerging hallmarks - deregulating cellular energetics and avoiding immune 
destruction - and two characteristics that enable the acquisition of all the previous hallmark 
capabilities: tumour-promoting inflammation and genome instability and mutation (Hanahan 
and Weinberg, 2011; Figure 1.4). 
Figure 1.4 The hallmarks of cancer. 
Douglas Hanahan and Robert Weinberg 
have suggested ten functional capabilities 
acquired during cancer development, 
providing a useful conceptual framework 
for understanding the complex biology of 
this condition (adapted from Hanahan and 
Weinberg, 2011). 
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1.1.4 Genome instability and mutation 
Genome instability and mutation is a particular hallmark, not being a functional capability 
of cancer per se, but a property that generates the genetic diversity that makes possible the 
acquisition of all the other hallmarks (Hanahan and Weinberg, 2011; Negrini et al., 2010). 
Supporting this view, tumours harbour too many mutations to be explained by anything other 
than underlying genomic instability (Sieber et al., 2003). Genomic instability is then defined 
as an increased propensity for DNA alterations, from single nucleotide to whole chromosome 
rearrangements, that usually is generated by compromising the surveillance systems that 
normally monitor genomic integrity (Pikor et al., 2013; Shen, 2011). 
Hereditary cancers are often characterized by the presence of mutations in DNA repair 
genes, such as BRCA1, BRCA2, MSH2 and MYH, which leads to genomic instability and 
consequent acquisition of mutations in oncogenes and tumour suppressor genes. Oppositely, 
in sporadic cancers the first alteration usually happens in oncogenes and tumour suppressor 
genes, promoting abnormal cell proliferation, with the resulting DNA replication stress 
(broadly defined as inefficient DNA replication characterized by DNA synthesis slow down 
and/or replication fork stalling) being responsible for the presence of genomic instability 
therein (Gaillard et al., 2015; Macheret and Halazonetis, 2015; Negrini et al., 2010). Genomic 
instability is therefore not only a hallmark of but also a driving force for tumourigenesis, 
promoting the acquisition of further DNA alterations, clonal evolution, and tumour 
heterogeneity (Sieber et al., 2003). 
Thus, cells need to keep their genome unharmed for proper cell function, resorting in four 
main mechanisms: high-fidelity DNA replication in S-phase, precise chromosome segregation 
in mitosis, error free repair of sporadic DNA damage, and a coordinated cell cycle progression 
(Shen, 2011). One subcellular organelle in animal cells critically implicated in the maintenance 
of genome stability is the centrosome (Lerit and Poulton, 2016). 
1.2 Centrosomes 
Centrosomes were identified more than one century ago by Edouard Van Beneden (Van 
Beneden and Neyt, 1887) and, almost simultaneously, by Theodor Boveri (Boveri, 1887). 
These organelles are the major microtubule-organising centre (MTOC) in animal cells, hence 
being pivotal for several fundamental cellular processes, including signalling, cell polarity and 
migration (Bettencourt-Dias and Glover, 2007; Stevens et al., 2007; Vinogradova et al., 2012; 
Wang et al., 2009). Furthermore, centrosome function in the organization of the spindle poles 
during mitosis is crucial for chromosome segregation and successful cell division (Bettencourt-
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Dias, 2013). Therefore, strict control of centrosome number and structure is critical to 
appropriate cell function. 
Centrosomes are found in most animal cells and comprise two centrioles, a mother and a 
daughter, surrounded by a complex proteinaceous structure, the pericentriolar material (PCM), 
which confers the microtubule nucleation capacity (Bettencourt-Dias and Glover, 2007; Gould 
and Borisy, 1977; Figure 1.5). Centrioles are small microtubule-based cylinders with a normal 
length ranging from 400 to 500 nm in human cycling cells. In addition to being the core 
centrosomal components, they function as basal bodies for the formation of cilia and flagella 
on the cell surface, which have crucial roles in physiology, development and disease (Badano 
et al., 2005; Carvalho-Santos et al., 2011; Praetorius and Spring, 2005). Normal cells in G0 or 
G1 phase of the cell cycle have a single centrosome that undergoes duplication once, and only 
once, in every cell cycle so that its number remains stable, like the genetic material of the cell 
(Nigg and Stearns, 2011). 
Figure 1.5 The centrosome. 
Centrosomes are composed by 
two, a mother (older) and a 
daughter (younger), centrioles, 
positioned in an orthogonal 
configuration, and surrounded by 
a complex proteinaceous structure 
called the pericentriolar material 
(PCM). The mother centriole 
shows subdistal and distal 
appendages where microtubules 
and the cell membrane are 
docked, respectively (adapted 
from Bettencourt-Dias, 2013). 
1.2.1 Centrosome cycle 
Centrosome duplication occurs at S phase in coordination with the cell cycle, where two 
new procentrioles (the future daughter centrioles) start forming adjacent to both the original 
mother centriole (now the grandmother centriole) and the original daughter centriole (now the 
mother centriole), and subsequently elongate until mitosis. There, the two newly formed 
centrosomes separate and migrate to opposite poles, allowing the bipolar spindle formation and 
faithful chromosome segregation. In the end of mitosis, centrioles disengage and, after 
cytokinesis, each of daughter cells has only one centrosome again, composed by one 
grandmother/mother (old) and one daughter (new) centriole (Bettencourt-Dias, 2013; Figure 
1.6). Interestingly, these centrioles differ in age and maturity and thus have different functions. 
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For instance, only the older centrioles recruit PCM and have centriolar appendages, and can 
hence initiate the assembly of the primary cilium, whereas daughter centrioles become 
competent only in the ensuing cell cycle (Hoyer-Fender, 2010). Moreover, the sister cell 
inheriting the grandmother usually grows the primary cilia faster (Anderson and Stearns, 2009). 
Figure 1.6 The centrosome duplication cycle. The centrosome cycle is tightly regulated in normal 
cells, to guarantee that each cell only has one centrosome. Procentriole formation begins in S phase, 
orthogonally to the proximal end of its mother centriole, and the subsequently elongation and 
maturation occurs during G2 phase. At mitosis, the newly formed centrosomes separate and direct the 
bipolar spindle assembly, segregating the chromosomes equally to the two daughter cells. Then the 
centrioles within each centrosome disengage, and after cytokinesis each of daughter cells will have one 
centrosome again, composed by one grandmother/mother (old) and one daughter (new) centriole 
(adapted from Bettencourt-Dias, 2013). 
Recently, the advent of sensitive proteomics and RNA interference (RNAi)-based screens 
have proved invaluable in identifying and studying the critical components of the centrosome 
and its duplication cycle (Andersen et al., 2003; Balestra et al., 2013; Bauer et al., 2016; 
Jakobsen et al., 2011). Although these analyses have revealed hundreds of proteins and 
considerable complexity, forward genetic and RNAi screens in C. elegans uncovered just five 
proteins essential for procentriole formation (Strnad and Gönczy, 2008).  
Among those proteins, the serine/threonine-protein kinase Polo-like Kinase 4 (PLK4, 
also known as SAK in Drosophila melanogaster and ZYG1 in C. elegans) has been 
demonstrated to be the master regulator of centriole biogenesis: in its absence centrioles fail to 
form, while its excess leads to centrosome amplification (CA) – the presence of more than one 
(or two, in mitosis) centrosome in a cell (Bettencourt-Dias et al., 2005; Habedanck et al., 2005; 
Kleylein-Sohn et al., 2007; O’Connell et al., 2001; Peel et al., 2007; Rodrigues-Martins et al., 
2007; Figure 1.7a). Proper centriole duplication is ensured by the regulation of PLK4 protein 
levels, mostly through SCF/Slimb ubiquitin-dependent proteolysis (Cunha-Ferreira et al., 
2009; Rogers et al., 2009). Together with PLK4, a module comprising also the two proteins 
STIL, a substrate of PLK4, and SAS-6 has been shown to stay at the core of centriole 
duplication (Arquint and Nigg, 2016). 
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Figure 1.7 PLK4 overexpression leads to centrosome amplification. a) SAK/PLK4 is the master 
regulator of centriole biogenesis and therefore its protein levels must be controlled, which is done 
mostly through SCF/Slimb ubiquitin-dependent proteolysis (Cunha-Ferreira et al., 2009; Rogers et al., 
2009). Low levels of SAK/PLK4 will lead to cells without centrosomes and, on the other hand, 
SAK/PLK4 accumulation, both by its overexpression or depletion of the SCF/Slimb complex, will 
result in centrosome amplification through simultaneous multiple procentriole formation (adapted from 
Cunha-Ferreira et al., 2009). b) Image illustrating centrosome amplification and consequent mitotic 
spindle multipolarity. Image of HeLa cell stably co-expressing EGFP–centrin-2 (green, reflecting 
centriole position) and stained for α-tubulin (red, reflecting microtubules) and DNA (blue). Insets are 
magnifications of the centrosomes (EGFP–centrin-2 signal) in the numbered poles (adapted from 
Maiato and Logarinho, 2016). 
1.2.2 Centrosome amplification and cancer 
Faithful control of centrosome number is dysregulated in a growing list of human 
tumours, particularly in more aggressive ones, leading to CA (Chan, 2011). Indeed, 
centrosomal abnormalities have been observed in several solid tumours, such as breast, 
prostate, colon, ovarian and pancreatic (Hsu et al., 2005; Lingle et al., 1998; Pihan et al., 1998; 
Sato et al., 1999), as well as haematological malignancies (Giehl et al., 2005; Krämer et al., 
2005). This is somewhat surprising given their deleterious effects on cell proliferation and that 
they are poorly tolerated by non-transformed cells (Ganem et al., 2009; Sluder and Nordberg, 
2004). Thus, these observations suggest CA as a candidate “hallmark” of tumour cells (Chan, 
2011). 
Over a 100 years ago, Theodor Boveri proposed for the first time that aneuploidy (the 
presence of an abnormal number of chromosomes in a cell) induced by CA promotes 
tumourigenesis (Boveri, 2008; Holland and Cleveland, 2009). Supporting his hypothesis, 
supernumerary centrosomes (Figure 1.7b) have been observed early in the development of 
several tumours, are implicated as the major mechanism underlying the generation of 
multipolar mitosis (Figure 1.7b), aneuploidy and genomic instability (a known hallmark of 
cancer), and often correlate with advanced tumour grade and poor clinical outcome (Ganem et 
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al., 2009; Godinho, 2015; Godinho and Pellman, 2014; Gonczy, 2015; Nigg, 2006; Nigg and 
Raff, 2009). Moreover, extra centrosomes have been shown to promote invasiveness, an 
important feature of tumourigenesis (Godinho et al., 2014). 
Such observations suggest CA could promote the initial stages of tumour development. 
However, whether this is a cause or consequence of tumourigenesis remains unclear. Recently, 
Levine and co-workers have tried to answer this question by chronically inducing CA in mice, 
by PLK4 overexpression, where they demonstrated that CA is sufficient to promote 
chromosome missegregation, aneuploidy, and the development of tumours in multiple tissues, 
supporting a direct causal relationship (Levine et al., 2017). This result gives more robustness 
to those of previous studies showing that CA can initiate tumourigenesis in flies overexpressing 
PLK4 (Basto et al., 2008) and PLK4 overexpression accelerates tumourigenesis in p53-
deficient mice (Coelho et al., 2015; Serçin et al., 2015). Together, they highlight centrosome 
abnormalities as critical promoters of tumourigenesis. 
1.2.2.1 Origins of centrosome amplification 
To clinically exploit CA, it is crucial to identify its aetiology. A number of mechanisms 
are known to experimentally induce supernumerary centrosomes, including cytokinesis failure, 
mitotic slippage (exiting mitosis without cell division), cell–cell fusion, and deregulation of 
the centrosome duplication machinery, leading to overduplication of centrioles and de novo 
centriole assembly (Godinho and Pellman, 2014; Godinho et al., 2009). However, little is 
known regarding their relative contribution to cancer, the existence of other origins or even 
their underlying molecular mechanisms. 
Until now, disruption of the centrosome duplication cycle appears as a major route to CA 
in cancer, namely through dysregulation of centriolar components both at protein or mRNA 
level (Godinho and Pellman, 2014). One good example are the high-risk human papillomavirus 
(HPV)-associated tumours, whose overexpression of the HPV-16 viral E7 oncoprotein induce 
CA through a process that involves increased PLK4 transcription levels (Korzeniewski et al., 
2011). Loss of p53 is not sufficient to generate CA (Marthiens et al., 2013) but it was shown 
to contribute to it. p53 might negatively regulate PLK4 mRNA levels (Li et al., 2005) and most 
importantly it monitors centrosome number through its checkpoint function, whose mechanism 
is not yet well understood (Fava et al., 2017; Fukasawa et al., 1996). In colon cancer, it was 
suggested that the frequently observed amplification of the Aurora-A gene leads to CA, as its 
overexpression leads to abnormal cytokinesis and supernumerary centrosomes (Ghadimi et al., 
2000; Lentini et al., 2007; Meraldi et al., 2002).
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Dysregulation of PCM components was also shown to play a role in promoting CA in 
cancer, for example by overexpression of pericentrin (Loncarek et al., 2008), an integral 
component of the PCM, or loss of the tumour suppressor BRCA1 (Starita et al., 2004), which 
regulates the PCM component J-tubulin. 
The absence of more extensive analyses of CA-associated mechanisms in cancer, largely 
due to associated technical challenges, is limiting our understanding of the CA role in cancer 
and preventing its use in the clinic. Therefore, it is crucial to integrate systematic surveys of 
centrosome structure with large-scale omic profiles. 
1.2.2.2 Coping with centrosome amplification 
CA promotes chaotic mitoses that pose a challenge for cell viability. How cancer cells 
control the detrimental consequences of CA is a very important question in cancer research, 
since the resulting aneuploidy degree will determine the outcome: moderate levels of genomic 
instability can induce tumourigenesis, whereas high levels can suppress it (Weaver et al., 
2007). While most non-transformed cells normally die or stop proliferating after multipolar 
mitosis, cancer cells can somehow cope with this abnormality and divide successfully, with an 
apparent “normal” bipolar mitotic spindle and controlled genome instability (Ganem et al., 
2009; Lingle and Salisbury, 1999; Ring et al., 1982). 
To supress multipolar divisions and cell death, cancer cells can inactivate, expel, 
segregate or cluster extra centrosomes (Godinho et al., 2009). Despite little being known 
regarding these mechanisms and their relative contribution to the “management” of CA, the 
most prevalent seems to be centrosome clustering (CC), where cancer cells cluster 
supernumerary centrosomes into two poles to assemble pseudo-bipolar spindles (Brinkley, 
2001; Godinho et al., 2009; Nigg, 2002; Zyss and Gergely, 2009). Previous studies, including 
two genome-wide RNAi screens (Kwon et al., 2008; Leber et al., 2010), uncovered, as the main 
classes of genes important for CC, i) microtubule-associated proteins, such as the motor protein 
HSET (encoded by KIFC1; Kwon et al., 2008), ii) proteins that induce spindle assembly 
checkpoint activation, providing a delay on mitosis that allows clustering to occur, and iii) the 
sub-cortical actin clouds, which create pulling forces on the centrosome via astral microtubules, 
a process dependent on Myosin 10 (Kwon et al., 2015). 
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1.2.2.3 Centrosome-targeting cancer therapies 
Altogether these findings highlight CA and associated cancer-specific adaptation 
mechanisms as potential targets for cancer therapy. Accordingly, there are currently in clinical 
trials drugs that prevent CA, such as PLK4 inhibitors (Mason et al., 2014). Given that normal 
cells do not rely on CC, pharmacological inhibition of this mechanism promises to selectively 
target tumour cells and HSET inhibitors are therefore under development (Watts et al., 2013; 
Wu et al., 2013; Yang et al., 2014). Furthermore, a previous screen has identified 14 
compounds that specifically induced multipolar spindles, by CC inhibition, in a breast cancer 
cell line containing extra centrosomes (Kawamura et al., 2013). 
Although CA-targeting therapies are appealing due to their potential selectivity, tumour 
heterogeneity should be considered. Tumours are heterogeneous populations of cells with and 
without CA and to date it is unclear how these approaches will affect tumour progression 
(Godinho and Pellman, 2014).  
Furthermore, it will be necessary to identify the patients who will benefit from such 
therapies. Immunostaining for centriolar components is currently the best laboratory method 
to quantify CA levels. However, although immunohistochemistry assays are already 
established in the clinic, particularly for breast cancer subtype classification (Blows et al., 
2010), their employment in CA-based patient stratification is still far from ready (Chan, 2011). 
A promising approach would be to identify a gene-expression-based signature that reflects the 
tumour CA levels. Indeed, Ogden and co-workers have recently developed a proof-of-principle 
score based on CA-associated gene expression levels that showed a prognostic value in breast 
tumours (Ogden et al., 2017). However, in order to bring such scores to the clinic, it will be 
necessary to characterize the transcriptomic changes associated with centrosome abnormalities 
and experimentally test if these scores really reflect the CA levels in the tumour. 
For all the aforementioned reasons, a comprehensive study of the molecular mechanisms 
behind centrosome abnormalities will allow to identify ways of selectively targeting this 
Achilles’ heel of cancer cells. 
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1.3 Screen of centriole number and structure in the NCI-60 panel 
Despite the recognized potential of CA in several aspects of cancer, such as aetiology and 
therapeutics, its incidence, origins and implications remain poorly understood. A recent study 
from Dr Mónica Bettencourt-Dias’ lab, led by Dr Gaëlle Marteil, addressed these questions by 
screening the NCI-60 panel of human cancer cell lines (Shoemaker, 2006), derived from 9 
distinct tissues, for centriole number and length, at a single-cell level (Marteil et al., manuscript 
in preparation). They have confirmed CA as a widespread phenomenon in cancer and have 
identified a new recurrent feature of cancer cells: centriole over-elongation (COE). Overly-
long centrioles generate over-active centrosomes that nucleate more microtubules, a known 
cause of invasiveness, and induce chromosomal instability. Furthermore, they showed that 
COE promotes CA through both centriole fragmentation and ectopic procentriole formation, 
thus identifying novel causes of that abnormality in cancer (Marteil et al., manuscript in 
preparation). 
The NCI-60 panel was developed in the late 1980s as an anticancer drug screen, with the 
main goal of identifying and characterizing novel compounds with potential anticancer activity 
on these cell lines, and has served the global cancer research community for more than 20 
years. This panel has data on cell line sensitivity for around 50.000 compounds, being the 
largest public database of anticancer drug activity. Moreover, these cell lines have been 
extensively characterized at genomic (including TP53 and ploidy status), transcriptomic and 
proteomic levels (Gholami et al., 2013; Leroy et al., 2014; Liu et al., 2010; Nishizuka et al., 
2003; Park et al., 2010; Roschke et al., 2003; Scherf et al., 2000; Shankavaram et al., 2007), 
allowing the study of diverse biological questions by the cancer community.  
Beyond the discovery of COE as a novel centriole abnormality in cancer and promoter of 
CA, the mentioned centriole screen provides for the first time a rigorous quantification of CA 
levels in a publicly characterized cell line panel. This unique resource will allow further 
insights on the CA-associated molecular mechanisms in cancer and the development of clinical 
applications based on targeting such aberrations. 
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CHAPTER 2 – AIMS 
The centriole profiles uncovered in the Bettencourt-Dias Lab, combined with the publicly 
available data of the NCI-60 cell lines, allow to both study the molecular origins of COE and 
CA and identify new compounds that selectively target cells with such abnormalities. 
Therefore, in my thesis project, I set up to: 
1. Profile the centriole abnormalities along the panel, going deeper into a single-cell 
and single-centriole level; 
2. Explore the molecular origins of such centriole abnormalities, correlating their 
prevalence along NCI-60 cell lines with the publicly available molecular data for the 
panel; 
3. Identify new compounds that target CA, either by selectively killing cancer cells 
with higher incidence of this abnormality or by targeting genes involved in its origins. 
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CHAPTER 3 – MATERIALS AND METHODS 
3.1 NCI-60 panel of human cancer cell lines 
The U.S. National Cancer Institute panel of 60 human cancer cell lines (NCI-60; 
https://dtp.cancer.gov/discovery_development/nci-60/) is composed by 60 cell lines derived 
from cancers from nine different human tissues/organs (blood, breast, central nervous system 
(CNS), colon, kidney, lung, ovaries, prostate and skin; Figure 3.1). These cell lines are very 
well characterized with publicly available information, including their tissue of origin, ploidy, 
TP53 status and doubling time (hours). Other parameters, such as sex and age of the donors, 
prior treatments and the histology of the respective tumour types, are also available. 
Figure 3.1 NCI-60 panel of human cancer cell lines. Each disc depicts a cell line. CNS, central 
nervous system. 
3.1.1 Screen of centriole number and length 
The centriole profiles of the NCI-60 cancer cell lines were obtained from a semi-
automated and systematic two-step survey, performed in Dr Mónica Bettencourt-Dias’ lab, 
aiming to quantify both centriole number and length (Marteil et al., manuscript in preparation; 
Figure 3.2). Importantly, as centriole number and length vary throughout cell cycle progression 
(Figure 1.6), the screen was restricted to mitotic cells to limit data variability, since these cells 
have four fully elongated centrioles (each around 500nm long in human cells). Quantifications 
were performed in three-dimensions (3D), given the small size of centrioles, and in at least 50 
mitotic cells, for each of the cell lines tested.  
All the 60 cell lines were analysed in a primary screening in which centrin was used to 
identify, count and measure centrioles. This marker localises very early to the distal end of 
centrioles, therefore maximizing their detection. In addition, centrin staining reflects centriole 
size, since the diameter of centrin dots increases as centrioles elongate, and this marker has 
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been successfully used in different centriole-related screens (Balestra et al., 2013; Loncarek et 
al., 2008; Piel et al., 2000; White et al., 2000; Zyss and Gergely, 2009). The primary screening 
allowed for the distinction of cell lines displaying CA and/or COE from the non-defective ones. 
However, centrin is also present in small electron-dense cytoplasmic granules called centriolar 
satellites that might have generated false positives in the primary screening (Dammermann and 
Merdes, 2002; Löffler et al., 2012; Van de Mark et al., 2015). To validate its results, all the cell 
lines displaying higher abnormality levels, as well as some less-defective ones (to test the 
presence of false negatives), i.e. a total of 52 cell lines, were then processed in a secondary 
screening. Here, centrin was used in combination with a second centriolar marker, CP110, to 
specifically label bona fide centrioles (structures positive for both markers), ensuring the 
absence of false positives. This secondary screening provided us with the centriole profiles 
(number and respective length) of 52 cell lines. For the remaining eight cell lines that were not 
incorporated in the secondary screening (low amplification and low elongation), we used their 
centriole profiles from the primary screening. In summary, for each of these 60 cell lines 
screened (eight from the primary and 52 from the secondary screening) we had the centriole 
number and respective length for at least 50 mitotic cells. 
Figure 3.2 Overview of the secondary screening of centriole alterations. First, the microscope was 
programmed to automatically acquire “Z” stack images, using a 100x objective, that were used to create 
maximum intensity projections (step 1). Mitotic cells were then identified, in a background of 
interphasic cells, based on DAPI and α-tubulin signals, both of which are brighter in mitotic cells (step 
2). Afterwards, centrioles were individually identified using centriolar markers (centrin and CP110 in 
the secondary screening; step 3) and segmented in three-dimensions (3D) using “Z” stacks (step 4). 
Finally, all centrioles were automatically split into individual centrioles and measured in 3D (step 5 and 
6). Centriole number and respective length per mitotic cell were stored, together with a gallery of 
annotated images. These galleries were manually curated twice at steps 3 and 5 (step 7), whereas all the 
remaining steps were automatically performed by the developed algorithm. Adapted from Marteil et 
al., manuscript in preparation. 
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Primary screening images were acquired on an Applied Precision DeltaVision CORE 
system, mounted on an Olympus inverted fluorescence microscope, using a 100x 1.4 NA Oil 
immersion objective. Secondary screening confocal image stacks were acquired on a 
Yokogawa CSU-X1 Spinning Disk confocal scan head, coupled to a Nikon Ti confocal 
microscope using a 100x 1.49 NA Oil immersion objective with 1.5x auxiliary magnification. 
The later has a pinhole system (a spinning disk with little holes) that minimize the photons 
coming from planes up and down the focal plane, giving images with more contrast than the 
ones obtained with the epifluorescence microscope (Marteil et al., unpublished data). 
3.1.1.1 Centriole abnormality metrics 
To profile the centriole abnormality level of each of the NCI-60 cell lines, we used two 
metrics: the percentage of cells with CA (more than four centrioles) and the percentage of cells 
with COE (at least one overly-long – longer than 500nm, twice the normal length measured 
using centrin staining – centriole; Annex 1). 
For single-cell and single-centriole analyses, we used only the centriole number and 
length quantifications resulting from the secondary screening (data available for only 52 cell 
lines: 12,927 centrioles in 2,842 cells), given the difference in the two screening 
methodologies. These quantifications were also used to generate two other metrics to 
characterize the centriole structure per cell line: the arithmetic mean of centriole number and 
length per cell (Annex 1). 
3.1.1.2 Centriolar mass 
The centriolar mass of each individual cell was calculated as the sum of its centrioles’ 
length. 
3.1.2 Centriole length regulators screen 
Our analyses of the NCI-60 panel identify one gene, PRKACA, that might regulate 
centriole length. Interestingly, this gene was already tested in an independent screen for 
putative centriole length regulators led by Dr Mariana Faria in Dr Mónica Bettencourt-Dias’ 
lab (unpublished data). In the human osteosarcoma U2OS cell lines, overexpressing PLK4, 
187 genes were individually knocked down, using three independent small interfering RNAs 
(siRNAs) per gene. In each siRNA experiment, the CEP135 and centrin protein intensity levels 
were measured (Figure 3.3a). CEP135 concentrates at the centriolar proximal ends and its 
intensity reflects centriole number (Fu et al., 2016), whereas centrin localises to the distal end 
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and its intensity increases as centrioles elongate (Loncarek et al., 2008). A decrease/increase 
in centrin intensity but no change in CEP135 intensity would reflect a decrease/increase in 
centriole length (Figure 3.3c). Variation in intensity levels was quantified in robust z-scores – 
number of median absolute deviation below or above the control (Scramble) median. 
Figure 3.3 Overview of the centriole length regulators screen. a) Briefly, human osteosarcoma 
U2OS cell lines, overexpressing PLK4, were knocked down for 187 genes individually, using three 
independent small interfering RNAs (siRNAs) per gene. CEP135 and centrin protein intensity levels 
were measured to reflect the centriole length. b) Example of HeLa cells immunostained with CEP135 
(red), centrin (green) and DAPI (blue, for DNA) antibodies (adapted from Seo et al., 2015). c) 
Illustration of how a decrease/increase in centrin intensity but no change in CEP135 intensity would 
reflect centrioles shorter/longer than the control. 
3.1.3 Flow Cytometry analysis of cell cycle phases 
The cell cycle profile of the NCI-60 cell lines was analysed by O’Connor et al., 1997, 
through fluorescence-activated cell sorting (FACS). In this approach, cellular DNA is labelled 
and cells are then sorted according to the fluorescence intensity, which reflects the amount of 
DNA within the cell, allowing to distribute them in three categories encompassing the four cell 
cycle stages: G1, S and G2/Mitosis (G2/M; Jayat and Ratinaud, 1993; Figure 3.4). The authors 
characterized each cell line for the cell cycle distribution in percentage of cells in each of the 
G1, S and G2/M phases. They also calculated the cell lines’ doubling time, which we compared 
with the recent doubling time estimates from the U.S. National Cancer Institute to confirm 
reproducibility of an experiment done twenty years ago. Indeed, estimated cell lines’ doubling 
times from both studies were correlated (Spearman correlation coefficient: 0.96, p < 0.0001; 
Annex 2). 
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Figure 3.4 Distribution of cells along the cell cycle 
phases. Measuring DNA content (using fluorescence 
intensity) allows to determine the percentage of cells in 
G1, S and G2/Mitosis (G2/M). The first peak represents 
diploid cells, before DNA replication, in G1 phase. Cells 
that are undergoing DNA replication at S phase have an 
increased amount of DNA, representing the space between 
the two peaks. After DNA replication, during G2 and 
mitosis, cells have the double of the G1 cells’ DNA and 
therefore the double fluorescence intensity, reflected on 
the second peak. 
3.1.4 Molecular and pharmacological data sets 
The NCI-60 panel has been largely characterized at the molecular and pharmacological 
levels, with the resulting information having been made publicly available in several databases. 
Most of the data sets can be accessed through the CellMiner web application 
(https://discover.nci.nih.gov/cellminer/loadDownload.do; Reinhold et al., 2012; Shankavaram 
et al., 2009), while others need to be accessed via the original papers, such as the global 
proteome analysis (Gholami et al., 2013). In this work, we focused on gene and protein 
expression and drug activity analyses. 
3.1.4.1 Gene expression 
The expression level of a gene can be measured using different technologies. One of the 
most important are microarrays – a collection of gene-specific nucleic acids probes attached to 
a solid surface at defined locations. The mRNA complement of a biological sample is 
converted into complementary DNA (cDNA), labelled (usually with a fluorescent dye), and 
then allowed to hybridize with the gene-specific probes on the array. Gene expression levels 
can thereby be quantified genome-wide by the fluorescence intensities measured across all 
spots on the array, assumed to be proportional to the amount of nucleic acid hybridized to the 
respective probes (John Quackenbush, 2001). 
Gene expression in NCI-60 cell lines has been profiled using different microarray 
platforms. Normalized gene expression values (averaged probe intensities combined from five 
microarray platforms) for the 60 cell lines were downloaded from the CellMiner. Probes 
containing missing values in more than 5% of cell lines (i.e. either with low sensitivity or 
associated with non-expressed genes) or a variance across samples lower than 0.1 (i.e. 
biologically non-informative; Annex 3) were removed from the analysis. After this quality 
control step, 19,676 genes remained for further analysis. 
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3.1.4.2 Protein expression 
The identification and quantification of the proteins expressed in a sample can already be 
done through high-throughput techniques. Mass spectrometry (MS) is one of the most 
commonly used and is based on the mass-to-charge ratio of ions. In this technique, proteins are 
enzymatically digested and the resultant peptide masses and fragment ions charges measured, 
allowing peptide identification through database searching. Finally, proteins are quantified 
from the correctly identified peptides that constitute them (Kolker et al., 2006). 
The NCI-60 global proteome was retrieved from Gholami et al., 2013, where 59 cell lines 
were analysed by MS-based proteomics. Relative protein abundance across samples was 
calculated from intensity-based label-free quantification. Peptides not quantified in more than 
50% of cell lines (more relaxed cut-off, compared with gene expression, given the lower MS 
detection efficiency), as well as probes with a variance across samples lower than 0.025 (Annex 
4), were removed from the analysis for the reasons described in section 3.1.4.1. 3,328 of the 
initial 8,113 proteins remained for further analysis. 
3.1.4.3 Drug sensitivity 
Activity data for 21,121 compounds were downloaded (on 6/1/2017; this list is frequently 
updated with new compounds) from CellMiner in z-transformed negative log10 of GI50 (the 
compound’s concentration that causes 50% growth inhibition) values, with higher values 
corresponding to higher sensitivity of cell lines to the respective drugs. These GI50 scores were 
measured based on a screen at five concentration levels (0.01, 0.1, 1, 10 and 100 µM) in each 
of the 60 cell lines (screening methodology explained in 
https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm). All these 
compounds have passed the NCI-60 quality control steps for data reproducibility and minimum 
variability across cell lines, and they include 158 Food and Drug Administration (FDA) 
approved and 79 clinical trial drugs. Furthermore, each of these drugs is annotated with its 
FDA status, mechanism of action, PubChem SID (Substance accession Identifier) and SMILE 
(Simplified Molecular Input Line Entry). 
Compounds with activity data for a minimum of 35 informative cell lines (as used in 
CellMiner: NCI-60 Analysis Tools, https://discover.nci.nih.gov/cellminer/analysis.do) and 
with a variance higher than 0.99 (Annex 5) were kept, for the reasons described in section 
3.1.4.1, accounting for 14,005 compounds.  
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3.2 Transcriptomic alterations associated with centriole abnormalities 
3.2.1 Centrosomal genes 
To identify genes putatively associated with centriole abnormalities, we focused on 
centrosomal genes retrieved from the CentrosomeDB - Centrosomal Proteins Database (Alves-
Cruzeiro et al., 2014; Nogales-Cadenas et al., 2009). 
3.2.2 Gene Set Enrichment Analyses 
Gene Set Enrichment Analyses (GSEA; Mootha et al., 2003; Subramanian et al., 2005) 
is a computational method that determines if an a priori defined gene set (for instance, a group 
of genes that share a biological function) shows statistically significant enrichment at the top 
(or bottom) of an ordered gene list (Figure 3.5a). This approach has the main advantage of 
considering information from all the studied genes, not only those above an arbitrary cut-off as 
commonly done by other knowledge-based functional enrichment analysis methods. GSEA 
also allows the users to create their own custom gene sets. 
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Figure 3.5 Overview of Gene Set Enrichment Analyses. a) GSEA uses molecular profile data (e.g. 
ordered gene list according with some phenotype) and a gene set database as input. It then tests the 
enrichment of each gene set at the top (or bottom) of the ranked list. An example of a gene set positively 
enriched, e.g. enriched on genes upregulated between two conditions, is shown (gene set result retrieved 
from Kammerer et al., 2011). b) An ordered gene list, ranked by the association with a phenotype (e.g. 
difference in gene expression between two groups, blue and red) is used in GSEA. For each gene set G, 
its members are considered hits, while non-member genes are considered misses. Then GSEA walks 
down the ordered gene list increasing a weighted running-sum statistic when it finds a hit (sums 1/Nh, 
where Nh is the number of hits) and decreasing when it finds a miss (subtracts 1/Nm, where Nm is the 
number of misses), so that the running-sum statistic starts and finishes at 0. Finally, the enrichment 
score (ES) is defined as the maximum deviation from zero (adapted from Subramanian et al., 2005). 
Briefly, the GSEA software (Mootha et al., 2003; Subramanian et al., 2005) sorts the list 
of genes in descending order, according to a chosen ranking criterion (e.g. fold-change of gene 
expression between two groups or correlation coefficient between gene expression and some 
phenotype), and walks it down, incrementing a running-sum statistic when a gene is in the gene 
set and decreasing when it is not. The increments are weighted according to the number of 
genes in the gene set, since the running-sum statistic should start at 0 and finish also at 0. Then, 
an enrichment score (ES) is defined as the maximum deviation from zero encountered when 
walking the list. Thus, gene sets enriched at the top of the gene list will have a higher positive 
ES, while gene sets enriched at the bottom will have a higher negative ES (Figure 3.5b). 
The significance of an observed ES (nominal p-value) is estimated by comparing it with 
a null distribution of ESs computed with randomly reordered gene lists. To allow the 
comparison of results across gene sets, the ESs of all gene sets are normalized to account for 
their sizes, yielding a normalized enrichment score (NES) for each set reflecting the observed 
enrichment’s effect size. The probability of a given gene set being a false positive finding is 
estimated by calculating the false discovery rate (FDR; Benjamini and Hochberg, 1995). 
The GSEA software (version 2.2.2) was run with gene sets retrieved from the KEGG 
database (Kanehisa and Goto, 2000; Kanehisa et al., 2016), that contains a collection of 
pathway maps associated with diverse biological functions. We used the GseaPreranked tool, 
that takes as input a ranked list of genes, with the default parameters. The input gene lists were 
ranked according to the Spearman correlation coefficients, ordered from 1 to -1, between 
gene/protein expression and centriole abnormalities levels. Gene sets with a FDR lower than 
5% were considered significant. 
3.2.3 Linear regression models to decouple independent effects 
When performing gene expression analyses, it is important to consider all sources of 
variation to ensure that results correspond to true biological events, and are not related to other 
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variables partially confounded with the phenotype of interest. One strategy to separate 
independent effects is to use linear regression models i.e. to test the hypothesized linear 
relationship between a dependent and one or more explanatory variables (simple or multiple 
linear regression, respectively; Lai et al., 1979). 
A model for a multiple linear regression that relates a dependent variable Y with n 
explanatory variables (X1, X2, …, Xn), given k observations, can be stated as 
Yi = β0 + β1X1,i + β2X2,i + … + βnXn,i + εi   for i = 1,2,…,k 
where β0 (also called the y–intercept) is the value of Y when all explanatory variables are 
null, βn (beta coefficients) represent the strength of the effect of each individual explanatory 
variable on the dependent variable, and ε is the error term. 
Linear regression models are frequently used in gene expression analyses, where Y 
represents the expression of a gene in k samples. In this context, the explanatory variables are 
usually phenotypic features that can be associated with changes in gene expression. Multiple 
linear regression models are used to decompose the independent effect of those phenotypes on 
gene expression. Afterwards, approaches as GSEA can be run on gene lists ranked according 
to the impact of each independent effect on gene expression. Linear regression models were 
implemented using the limma R package (Ritchie et al., 2015) and genes were ranked by the 
moderated t-statistic for differential expression. For each gene, the moderated t-statistic was 
calculated as the ratio between the base 2 logarithm of the fold-change in expression and the 
moderated standard error of the base 2 logarithm of expression across samples. Standard errors 
were moderated across genes using an empirical Bayesian model that borrows information 
from the ensemble of genes to help inference about each individual gene (Smyth, 2004). 
3.3 Statistical hypothesis testing 
The main aim of statistics is to test a hypothesis (Witte and Witte, 2013). A hypothesis is 
a proposed explanation, often called an “educated guess”, for a phenomenon, that should be 
testable, either by experiment or observation. Hypothesis testing compares two hypotheses: the 
null hypothesis encodes for “nothing happening”, whereas the alternative hypothesis states that 
there is relation between phenomena, which is usually the working hypothesis of the 
researcher. Hypothesis testing has three main steps: state the null hypothesis, choose the 
appropriate statistical test to perform, and in the end assess if there is enough evidence to reject 
the null hypothesis, usually based on a p-value. The p-value (or probability value) is the 
probability of rejecting the null hypothesis when it is true. Thus, the lower the p-value, the 
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higher the confidence in rejecting the null hypothesis and accepting the researcher’s working 
one (Greenland et al., 2016; Sedgwick, 2014; Shaw and Proschan, 2013; Witte and Witte, 
2013). 
Statistical tests can be parametric or non-parametric, their choice mainly depending on 
how the observed data are distributed. A parametric test makes assumptions about the data 
distribution (e.g. the data is normally distributed) whereas a non-parametric one makes no such 
assumptions. The latter is less powerful because it uses less information, since it sorts the data 
by magnitude and replaces observed values with their ranks, but it is also less biased by outliers 
and misassumptions about distributions (Conover, 1971; Sedgwick, 2015).  
In the present work, different statistical tests were used, according to the different null 
hypotheses under examination. All the statistical analyses and graphics were performed using 
the R free software environment (R Core Team, 2017). R is a language and environment that 
provides a wide variety of statistical and graphical techniques, and is highly extensible due to 
a vast range of freely available packages. Most of the graphics displayed in this work were 
generated using the ggplot function from the ggplot2 R package (Wickham, 2009). 
 
3.3.1 Unpaired and paired two-sample statistical tests 
The Wilcoxon signed-rank test (Wilcoxon, 1945) is a non-parametric test used to 
compare repeated measurements on a single sample (one-sample) or two paired samples (i.e. 
each measurement in one sample is uniquely paired with a measurement in the other sample, 
resulting in pairs of observations). The one-sample version is the analogue of the parametric 
independent one sample t-test and tests the null hypothesis “the median of the sample is equal 
to a known standard value (i.e. theoretical value)”. The paired version is used for the null 
hypothesis “the median difference between pairs of observations is zero”. The last is the 
alternative to the parametric paired Student's t-test, where the null hypothesis is “the mean 
difference between pairs is zero”.  
When comparing two unpaired samples, a Wilcoxon rank-sum test (also known as the 
Mann-Whitney U test) should be used. It is the non-parametric alternative to the unpaired 
Student's t-test and tests the null hypothesis “the median of two samples are equal” or “both 
samples are from populations having the same distribution”. 
Both the Wilcoxon signed-rank and rank-sum tests were implemented using the 
wilcox.test function provided by the stats R package (R Core Team, 2017). 
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3.3.2 Kruskal-Wallis rank-sum test 
The Kruskal-Wallis rank-sum test (Kruskal and Wallis, 1952) is an extension of the 
Wilcoxon rank-sum test for more than two samples. It is a non-parametric method for testing 
whether different samples originate from populations with the same distribution, where the null 
hypothesis is that the samples’ medians are the same. 
This test was performed using the kruskal.test function provided by the stats R package. 
3.3.3 Fligner-Killeen test of homogeneity of variances 
The Fligner-Killeen non-parametric test (Conover et al., 1981) was used to assess the 
assumption of equality of variances between two or more groups, under the null hypothesis 
that the groups’ variances are equal. It is very robust against departures from normality and 
outliers. 
This test was performed using the fligner.test function provided by the stats R package. 
3.3.4 Unsupervised hierarchical clustering 
Unsupervised hierarchical clustering is an exploratory data analysis technique used to 
group similar objects into clusters. Similarity is calculated based on inter-object distance 
measures, including Euclidean (square root of the sum of the squares of the differences between 
coordinates) and correlation-based (calculated by subtracting from 1 the coefficient of 
correlation between objects) ones, where shorter distances reflect more similar samples. Each 
object is initially considered as a cluster of its own. Then, the two most similar clusters are 
successively combined until all objects are in the same cluster. The result is a tree-based 
representation of the objects, also known as dendrogram, that shows the hierarchy of the 
different clusters (Everitt, 1974). 
Unsupervised hierarchical clustering was computed using the heatmap.2 function 
provided by the gplots R package (Warnes et al., 2016). 
3.3.5 Spearman’s rank correlation 
Spearman’s rank correlation (Spearman, 1904) is a non-parametric measure of the 
statistical dependence between two paired variables that assesses their monotonic relationship. 
In short, it ranks the values from smallest to largest within each variable and then compares 
paired ranks. Under the null hypothesis that “the ranks of two variables do not covary”, the test 
calculates Spearman’s correlation coefficient, that varies between -1 (negative correlation) and 
1 (positive), and the respective p-value.  
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This test was executed using the cor.test function provided by the stats R package. 
3.3.6 Analyses of covariance (ANCOVA) 
Analysis of covariance (ANCOVA) combines analysis of variance (ANOVA) and linear 
regressions. It is used to compare two or more regression lines by testing the effect of a 
categorical factor (i.e. different groups) on a linear relationship between a continuous covariate 
(x-var) and a response variable (y-var), under the null hypothesis that slopes of different 
regression lines are equivalent, i.e. regression lines are parallel between groups (Borm et al., 
2007; Miller and Chapman, 2001). 
To compare two or more regression lines, the relation between variables is split into 
several linear equations, according to the categorical factor levels. Then, the interaction of the 
categorical factor on that relation is measured. As exemplified in Figure 3.6, when the response 
follows the same trend in two groups, the group factor does not affect the association between 
variables, i.e. there is no interaction (Figure 3.6a). If the interaction is significantly different 
from zero, it means that we can reject the null hypothesis: the categorical factor group affects 
the relation between the covariate and the response variable and, therefore, regression lines 
have different slopes between groups (Figure 3.6b; Fuchs, 2011). 
Figure 3.6 Comparing two regression slopes with ANCOVA. Analysis of covariance (ANCOVA) 
tests the null hypothesis that slopes of different regression lines, that model the relation between a 
covariate and a response variable in different categorical factor levels (groups), are equivalent. a) If the 
factor Group does not influence the linear relationship between variables, it means that there is no 
significant interaction and both slopes are parallel. b) When the effect of the covariate on the response 
variable depends on the sample group, the interaction is significantly different from zero and the 
regression lines have different slopes (adapted from Fuchs, 2011). 
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In the context of this work, the continuous variables are CA and COE per cell line, and 
the levels of the categorical factor are the different NCI-60 cancer tissues. This test was done 
using the aov function provided by the stats R package. 
3.3.7 Pearson's chi-squared test 
3.3.7.1 Chi-squared test of independence 
Pearson's chi-squared test is a non-parametric method commonly used to determine 
whether there is a significant association between two categorical variables, each with two or 
more levels. It converts categorical variables into a 2-dimensional contingency table and tests 
the null hypothesis “the two variables are independent”. If those variables are independent, the 
expected value for each cell of the contingency table is: the sum of all cells in its row multiplied 
by the sum of all cells in its column, then divided by the sum of all cells in the table. The test 
compares the observed values with the expected ones and, if the null hypothesis is rejected, it 
means that those variables are not independent and there is a relation between them (Mchugh, 
2013; Yates, 2012) 
This test was performed using the chisq.test function provided by the stats R package. 
3.3.7.2 Chi-squared goodness of fit test 
Pearson's chi-squared goodness of fit (Chernoff and Lehmann, 1954) is a non-parametric 
test used to compare the observed frequency distribution with that expected, when analysing a 
single categorical variable with two or more levels. In this case, the null hypothesis being tested 
is whether the observed proportions equal the expected ones. 
This test was performed using the chisq.test function provided by the stats R package. 
3.3.7.3 Generate a random distribution of COE per cell 
A distribution of COE per cell in the NCI-60 panel is generated by counting the number 
of cells (within the total 2,842) with each amount of longer centrioles (e.g. 0, 1, 2, ..., n) and 
can be illustrated by a histogram. 
To generate a random (i.e. expected by chance) distribution of COE per cell, we 
performed 1000 permutations on centriole length data (for 12,947 centrioles), randomizing all 
centriole lengths across all cells, and, for each permutation, we counted the number of cells 
with each amount of longer centrioles. Finally, we summarized the results of 1000 
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permutations, using the mean and respective standard error for each amount, in an overall 
random distribution of COE per cell (Figure 3.7). 
Figure 3.7 Generate a random distribution of COE per cell. A table with all centriole lengths per 
cell was generated, with data for 12,947 centrioles distributed by 2,842 cells. The longer centrioles 
(more than 500nm) are highlighted in bold (column 2) and the number of longer centrioles, per cell, is 
represented in column three. To generate the expected-by-chance distribution, the column with centriole 
length information was randomly permutated 1000 times (blue arrow) and, for each permutation, the 
counts of column three were recalculated. Then, for each permutation, the number of cells with each 
amount of longer centrioles (e.g. 0, 1, 2, ..., n) was counted. Finally, the results of those 1000 
permutations were summarized in an overall distribution, using the mean and respective standard error 
for each amount of longer centrioles. 
3.3.8 Binomial test 
The binomial test is used when an experiment has two possible outcomes (i.e. 
success/failure) and compares the observed proportion of successes with a hypothesized 
probability of success. It tests the null hypothesis that the observed probability of success is 
equal to the hypothesized one (Conover, 1971).  
This test was implemented using the binom.test function provided by the stats R package. 
3.3.9 Correction for multiple testing 
Statistical analysis can involve the simultaneous testing of many hypotheses. The more 
hypotheses are tested, the higher the chances of getting significant results just by chance. For 
example, a p-value of 0.05 means a probability of 5% of rejecting the null hypothesis when it 
is true. Thus, when performing 100 statistical tests, and assuming for all of them the null 
hypothesis is true, one expects about five of them to be significant at that p-value, with the null 
hypothesis being rejected just due to chance (the so-called false positives). Therefore, if the 
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interest is to find observations yielding enough evidence to reject the null hypothesis, p-values 
should be corrected for multiple testing to adjust the associated statistical confidence according 
with the number of tests performed (Noble, 2009). 
We used the false discovery rate (FDR) method (Benjamini and Hochberg, 1995), that 
controls for the expected proportion of false positives (i.e. rejections of the null hypothesis 
when it actually holds) in the correction of nominal p-values for multiple testing. Each FDR-
corrected p-value is calculated by multiplying the nominal p-value by the number of tests and 
then dividing it by its rank amongst all the nominal p-values sorted in ascending order (smallest 
to largest). 
This approach was implemented using the p.adjust function provided by the stats R 
package. 
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CHAPTER 4 – RESULTS 
4.1 Profile of centriole abnormalities in the NCI-60 panel 
The NCI-60 screen of centriole number and length provided a comprehensive landscape 
of centriole abnormalities in different cancer cell lines and tissues. To compare the frequencies 
of centriole defects in different cancer types, we chose two metrics that capture abnormality 
levels in their number and length: the percentage of cells with CA and the percentage of cells 
with COE in each cell line. 
CA was more frequent than COE in cancer cell lines (means equal to 17% and 5% of 
cells, respectively; paired Wilcoxon signed-rank test p < 0.0001) and none of these centriole 
abnormalities was specific for any primary tumour type from which the cell lines were derived. 
Cell lines from all different primaries exhibited some degree of abnormality both at number 
and length levels (Figure 4.1a,b). Yet, lung cancer was the primary histology with the highest 
variability in both abnormalities. 
All cell lines had some level of CA, except the control UO-31 (Figure 4.1c). In contrast, 
only 41 cell lines (68%) had length abnormalities (Figure 4.1d). The skin cancer cell line 
MDA-MB-435 was the one with the most extreme COE within the panel. 
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Figure 4.1 Profile of centriole abnormalities in the NCI-60 panel. Percentage of cells with (a,c) CA 
and (b,d) COE for each (a,b) primary cancer histology and (c,d) cell line, coloured by tissue of origin 
and ordered by abnormality level (in the case of cell lines). 
4.1.1 Single-cell and single-centriole heterogeneity in cancer 
Studies on centriole abnormalities are usually done at a cell population level, whereas the 
prevalence and heterogeneity of these abnormalities in cancer at single-cell (for centriole 
number), and even single-centriole (for centriole length), level remain unknown. Taking 
advantage of the single-centriole resolution of the NCI-60 screen, we went deeper in the 
profiling of those abnormalities in that cancer cell line panel. 
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4.1.1.1 Centriole number 
Although cell lines from all origins presented cells with different amounts of centrioles, 
we observed different variances of number of centrioles per cell between primary cancer tissues 
(Fligner-Killeen p < 0.0001; Figure 4.2).  
Figure 4.2 Distribution of the number of centrioles per cell across NCI-60 tissues of origin, 
coloured by cancer cell line. Each dot corresponds to a cell. Violin plots were created based on segments 
connecting frequencies at each integer (from one to ten centrioles/cell), given that centriole number is 
a discrete variable. 
However, for each primary tissue, about 70% of cells had four centrioles, making it 
difficult to define a metric for single-cell CA heterogeneity. Given that difficulty, we have 
characterized each primary tissue’s heterogeneity based on the cumulative distribution of the 
number of centrioles per cell across cells (Figure 4.3a). Tissues with higher CA heterogeneity 
were therefore expected to exhibit lower cumulative distribution values for more than four 
centrioles. Indeed, despite blood cancer cell lines being those with the largest proportion of 
cells with CA, colon and lung cancer ones presented overall the highest CA dispersion among 
the panel (Figure 4.3a). 
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To group tissues according to their CA heterogeneity, we compared centriole number 
variance in all combinations of pairs of tissues of origin, using the Fligner-Killeen non-
parametric test. Unsupervised hierarchical clustering based on the resulting p-values (more 
precisely, minus their base 10 logarithm) suggests three main groups: colon and lung cancer 
tissues with higher heterogeneity; prostate, skin, breast and blood with an intermediary 
dispersion level; CNS, ovaries and kidney with lower CA dispersion (Figure 4.3b and Annex 
6a). Remarkably, we observed in all tissues more cells with eight than with seven centrioles 
(Figure 4.3b). 
Despite those differences across tissues, centriole number distributions were similar 
between cell lines with the same tissue of origin (data not shown).  
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Figure 4.3 Centriole number heterogeneity in cancer. a) Cumulative distribution of the number of 
centrioles per cell, with cells grouped by tissue of origin (fainter lines). Dark lines connect the “jumps” 
in the respective discrete cumulative distributions. b) Histograms (percentage of cells) of the number 
of centrioles per cell, grouped and coloured by tissue of origin. Only percentages for cells with one to 
ten centrioles are shown but they were calculated based on all the cells for each tissue of origin. Tissues 
are hierarchically clustered (Euclidean distances calculated based on Fligner-Killeen p-values across 
all combinations of tissue pairs) and the three main clusters are highlighted. The associated heatmap of 
distances is shown in Annex 6a. 
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4.1.1.2 Centriole length 
Centriole length variability was also observed across different tissues of origin (Fligner-
Killeen p < 0.0001; Figure 4.4). Like centriole number, we performed unsupervised 
hierarchical clustering based on Fligner-Killeen p-values across all possible combinations of 
tissue pairs. We observed three main clusters, with lung and skin constituting that of higher 
length heterogeneity and ovaries the one with lower heterogeneity (Figure 4.4 and Annex 6b). 
It should be noted that we observed some extremely long centrioles in the HOP-62 lung cancer 
cell line, including the longest centriole within the screen, which was 5,339nm long (more than 
ten times longer than a normal-length centriole). 
Figure 4.4 Centriole length heterogeneity in cancer. Length of individual centrioles (nm) distributed 
across the NCI-60 tissues of origin, coloured by cancer cell line. Violin plots of the respective 
distributions are shown. Tissues are hierarchically clustered (Euclidean distances calculated based on 
Fligner-Killeen p-values across all combinations of tissue pairs) and the three main clusters are 
highlighted with bars in different shades of grey. The associated heatmap of distances is shown in Annex 
6b. The Y-axis is in logarithmic scale. Horizontal dashed line at 500nm represents the stipulated 
maximal length of a normal-length centriole. 
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Interestingly, even within individual tissues of origin there were big discrepancies in 
length variability across cell lines (Figure 4.4). Indeed, within skin and lung cancers (those 
with higher centriole length heterogeneity), different cell lines had different centriole length 
variances (Fligner-Killeen test p < 0.0001 in both cases; Figure 4.5). 
Length heterogeneity in skin cancer (Figure 4.5a) was mainly due to cell line MDA-MB-
435 (statistically significant higher variance than those of all other skin cancer cell lines: 
Fligner-Killeen test FDR-adjusted p-value < 0.001), also the one with the highest penetrance 
of COE in the panel (Figure 4.1d). Particularly, and contrasting with the higher abnormality 
levels of the MDA-MB-435 cell line, UACC-257 did not have any overly-long centriole and 
its centriole length distribution is narrower. 
For lung cancer cell lines (Figure 4.5b), we observed four cell lines with almost no 
overly-long centrioles (A549 (0% of cells with COE), NCI-H460 (0%), NCI-H322M (1.9%) 
and NCI-H522 (3.9%); Figure 4.1d) and three with high COE levels (HOP-92 (17.3%), NCI-
H23 (19.6%) and HOP-62 (29.3%); Figure 4.1d), explaining the higher overall COE variability 
observed in lung cancer cell lines (Figure 4.1b). Particularly, cell line HOP-62 was the one 
showing the highest length heterogeneity (statistically significant higher variance than those of 
all other lung cancer cell lines: Fligner-Killeen test FDR-adjusted p-value < 0.001; Figure 
4.5b). 
Figure 4.5 Single-centriole length heterogeneity in individual cell lines for selected tissues of 
origin. Distributions of centriole length (nm) for different cell lines derived from (a) skin and (b) lung 
cancer tissues. The respective violin plots are shown. Cell lines are ordered by centriole length variance 
and the ones with higher length heterogeneity (i.e. showing statistically significant higher variance 
than those of the remaining cell lines) are highlighted with respective colours from Figure 4.4. Y-axis
and horizontal dashed line as in Figure 4.4.
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4.1.2 Aggressive breast and colon cancer cell lines display high levels of CA 
We noticed that CA was more prevalent in specific aggressive subtypes of breast and 
colon cancer (Kocarnik et al., 2015; Parker et al., 2009; Phipps et al., 2015; Sørlie et al., 2001). 
Cell lines from the basal breast cancer molecular subtype displayed higher CA than luminal 
ones (Figure 4.6a) and, similarly, CA was more frequent in the most common subset of colon 
carcinoma, CIN (chromosomal instable, microsatellite stable), than in MSI-H cell lines 
(microsatellite instable, hyper-mutated; Figure 4.6b). Breast cancer findings were 
subsequently validated in human tissue samples, in Dr Joana Paredes’ lab (Instituto de 
Investigação e Inovação em Saúde; Marteil et al., manuscript in preparation), supporting the 
results of this systematic survey and suggesting that CA specifically occurs in more aggressive 
tumour subtypes. 
Figure 4.6 NCI-60 cell lines from aggressive breast and colon cancer subtypes display high levels 
of centrosome amplification. Percentage of cells with CA for each cell line from different (a) breast 
(Luminal and Basal) and (b) colon (MSI-H, microsatellite instability, and CIN, chromosomal 
instability) cancer molecular subtypes. Given the low sample size, no statistical test was performed 
between subtypes. 
4.1.3 COE and CA are not independent 
Since COE were shown to promote CA in vitro (Marteil et al., manuscript in 
preparation), we then tested the association between both abnormalities in the NCI-60 panel 
at the cell line level. Indeed, COE was significantly positively correlated with CA (Spearman 
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correlation coefficient: 0.4, p < 0.01; Figure 4.7a). We have also observed the existence of cell 
lines with high levels of CA but reduced COE (bottom right corner of Figure 4.7a), contrasting 
with the absence of cell lines with high COE but low CA (top left corner of Figure 4.7a). 
However, this association was different between tissues of origin (ANCOVA p < 0.05; 
Figure 4.7b), likely because only skin, lung and kidney cancer tissues had enough variability 
on COE levels (Figure 4.1b). In summary, for tissues with variability at both number and length 
abnormality levels, COE was associated with CA. 
Figure 4.7 Centriole over-elongation was positively correlated with centrosome amplification. a) 
Comparison between percentage of cells with CA and percentage of cells with COE on NCI-60 cell 
lines (Spearman correlation coefficient: 0.4, p < 0.01). The grey shade around the blue linear regression 
line represents its 95% confidence interval. b) The same as a) but with cell lines coloured according to 
their tissue of origin and a regression line represented for each tissue. Regressions were significantly 
different between tissues (ANCOVA test p < 0.05). 
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We also examined if there was an association between both abnormalities at the single-
centriole level. Indeed, we observed statistically significant differences in centriole length 
between cells with different numbers of centrioles (Kruskal-Wallis rank-sum test p < 0.0001; 
Figure 4.8).  
One cell with 32 centrioles, from the skin cell line MDA-MB-435, exibhited a particular 
enrichment of overly-long centrioles. This cell had a centriole length median of 420nm and 
34% (11 out of 32) of overly-long centrioles, contrasting respectively with 280nm (Wilcoxon 
rank-sum test p < 0.0001) and 1.54% (Chi-squared test of independence p < 0.0001) throughout 
the dataset. 
Figure 4.8 Distribution of centriole length according to the number of centrioles per cell. 
Comparison of single-centriole length (nm) across cells with different numbers of centrioles (12,927 
centrioles from 2,842 cells; Kruskal-Wallis rank-sum test p < 0.0001). Box plots and the number 
of cells per group are shown. Y-axis and horizontal dashed line as in Figure 4.4. 
We then hypothesized that CA and COE were related at single-centriole level and tested 
the null hypothesis of independence between abnormalities, where one would expect the same 
proportion of overly-long centrioles within cells with or without CA (1.54% of centrioles in 
each group). However, we observed a statistically significant higher proportion of overly-long 
centrioles in cells with CA (2.53%, compared with 1.13% in cells without CA; Chi-squared 
test of independence p < 0.0001; Figure 4.9). This result led us to reject the null hypothesis 
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and accept the alternative one that COE and CA are not independent, i.e. there is a relation 
between those abnormalities. 
Figure 4.9 Centriole over-elongation and centrosome amplification are not independent. Higher 
proportion of overly-long centrioles (>500nm) in cells with CA (12,927 total centriole number; p < 
0.0001, Chi-squared test of independence), compared with the expected proportions under the null 
hypothesis of independence. The expected and observed percentages of overly-long centrioles in cells 
with normal centriole number (Normal) and CA are shown, together with a detailed view above, given 
the low frequency of overly long centrioles. 
4.1.4 COE is not a stochastic event in cancer cells 
In the present dataset, we observed only 1.54% (199 out of 12,927) of overly-long 
centrioles, within 5.88% (167 out of 2,842) of all cells (Figure 4.10). More precisely, 5.14%, 
0.63% and 0.13% of cells (146, 18 and 3 out of 2,842, respectively) had one, two, and more 
than two overly-long centrioles, respectively. The lower frequency of COE suggests it as a rare 
phenomenon in cancer. 
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Figure 4.10 Centriole length dysregulation does not affect all centrioles within the same cell. 
Distribution of the number of overly-long centrioles (0, 1, 2 and more than 2) in each cell from the 
secondary screening, coloured by tissue of origin. Most cells with centriole length abnormalities 
(detailed view on box) only have one centriole affected by over-elongation. 
To determine whether the COE distribution observed in this cancer panel is similar to a 
typical one of a rare event, we first generated a random distribution of COE per cell (Figure 
4.11a,b - Expected). This distribution represented the expected frequencies of over-elongation 
within cancer cells, as if it was a stochastic event. Then we compared the observed frequencies 
(Figure 4.11a,b - Observed) with the expected ones, under the null hypothesis that both 
frequencies are equal. We found a significant difference between the observed frequencies of 
COE and the expected ones (Chi-squared goodness of fit test p < 0.0001; Figure 4.11), 
suggesting that this feature is not a completely stochastic event in cancer cells. Particularly, we 
observed a higher frequency of cells with more than one overly-long centriole than what is 
expected by chance (Figure 4.11b). 
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Figure 4.11 Centriole over-elongation is not a stochastic event in cancer cells. Comparison of the 
expected (calculated from a random distribution) and observed distributions of the number of overly-
long centrioles (0, 1, 2 and more than 2) per cell within (a) all cells or (b) cells with COE. Significant 
differences were observed: Chi-squared goodness of fit test p < 0.0001. 
4.1.5 COE is cell state-dependent 
Since COE was not deemed to be a completely stochastic event, with the frequency of 
cells with more than one overly-long centriole being higher than expected by chance (Figure 
4.11b), we investigated if the cell state (physiological condition of a given cell) could be 
influencing the frequency of this abnormality. Namely, our hypothesis was that cells with 
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already one overly-long centriole had a tendency to have another overly-long centriole. To test 
this hypothesis, we used the binomial test, where we considered a cell with more than one 
overly-long centriole as a success, within all cells with COE (i.e. at least one overly-long 
centriole). Then we compared the number of successes observed in the panel with a 
hypothesised probability of success calculated from the COE random distribution. We 
observed a significantly higher proportion of successes in the observed distribution (one-tailed 
Binomial test p < 0.0001; Figure 4.11b), meaning that COE occurred more frequently within 
the same cell and, thus, is a cell state-dependent feature. 
However, this observation can differ between cells with four centrioles and cells with 
CA. To address this question, we took the same approach, but now independently for each of 
those groups of cells. For each group, we have generated a random distribution of COE per cell 
and calculated the expected frequencies of cells with one, two, and more than two overly-long 
centrioles (Figure 4.12). Then, we again performed binomial tests. We observed, in both cases 
(within the 95 cells with four centrioles and COE, and within the 68 cells with CA and COE), 
a significantly higher proportion of cells with more than one overly-long centriole than 
expected by chance (one-tailed Binomial test p < 0.05 and p < 0.001, respectively; Figure 
4.12). 
Regarding cells with four centrioles and COE, five of the 95 (5.26%) exhibited two 
overly-long centrioles and no cells were found with more than two. The latter could be 
explained by the insufficient number of observations, since, by chance, one would expect 
0.01% of cells to have more than two overly-long centrioles, i.e. less than one cell out of 95 
(frequencies from the random distribution; Figure 4.12a). 16 of the 68 (23.5%) cells with both 
CA and COE exhibited two or more overly-long centrioles, contrasting with the expected 
9.62% (Figure 4.12b). These observations suggest COE as a widely cell state-dependent 
feature. 
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Figure 4.12 Centriole over-elongation is a cell state-dependent feature. Higher proportion of cells 
(Observed) with more than one overly-long centriole than expected by chance (calculated from a 
random distribution) within (a) cells with four centrioles and COE (one-tailed Binomial test p < 0.05) 
and (b) cells with both CA and COE (one-tailed Binomial test p < 0.01). 
4.1.6 Total centriolar mass per cell is apparently not controlled 
Given this phenomenon of centriole length dysregulation in cancer, we then tested if 
cancer cells still control their centriolar mass (given by the sum of centrioles’ length) when 
centriole number increases. If they control it, one would expect constant centriolar mass in 
cells with supernumerary centrosomes, i.e no statistical association between the number of 
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centrioles and the sum of centrioles’ length. However, we observed that centriolar mass 
increased monotonically with the number of centrioles within the cell (Spearman correlation 
coefficient: 1, p < 0.0001; correlation between mean of centriolar mass, per group of cells with 
the same number of centrioles, and this number of centrioles per cell), suggesting that cancer 
cells do not control their centriolar mass (Figure 4.13a).  
Next, we investigated if there was any evidence that CA arose from centriole 
fragmentation, one of the mechanisms proposed by Marteil and co-workers (Marteil et al., 
manuscript in preparation). If this hypothesis was true, one would expect that cells with CA 
had shorter centrioles, putatively resulting from fragments, and the mean of centriole length 
per cell would be negatively associated with its centriole number. We found no association 
between those variables (Spearman correlation coefficient: -0.01, p: n.s. (not significant); 
correlation between mean of centriole length, per group of cells with the same number of 
centrioles, and this number of centrioles per cell; Figure 4.13b). Since the mean of centriole 
length was maintained in cells with supernumerary centrosomes, there was no evidence, in this 
panel of cell lines, that CA arose from centriole fragmentation. 
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Figure 4.13 Centriolar mass increased in association with the number of centrioles within the cell, 
while centriole length mean was maintained. Distribution of (a) centriolar mass (sum of centrioles’ 
length per individual cell; nm) and (b) mean of centriole length (nm) across cells with different number 
of centrioles (2,842 cells; Spearman correlation coefficient: 1 (p < 0.0001) and -0.01 (p: n.s.), 
respectively). Lines connecting group means (blue shades represent their associated 95% confidence 
interval) and the numbers of cells per group (at the bottom) are shown. Horizontal dashed lines at (a) 
2000nm and (b) 500nm represent the stipulated maximums of centriolar mass (as in cells with four 
normal-length centrioles, i.e. 4 times 500nm) and length of a normal centriole, respectively. The Y-axis 
is in logarithmic scale. 
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4.2 Discovery of novel molecular origins of centriole abnormalities in cancer 
The molecular origins of centriole abnormalities in cancer were studied by integrating 
their prevalence with publicly available molecular data for the NCI-60 panel. In addition to the 
percentage of cells with CA and COE metrics, that reflect the prevalence of these abnormalities 
at the cell line level, we used the single-centriole data to generate two other metrics that 
characterize the centriolar landscape per cell line: the means of centriole number and length 
per cell (Annex 1). Together, the four metrics complementarily depicted different features of 
centriolar abnormalities and were used in the following analyses. 
 
4.2.1 Cancer cell lines with overly-long centrioles have more cells in G1 
We started by investigating a putative relationship between centriole abnormalities and 
cell proliferation rates, taking advantage of the publicly available data on NCI-60 cell line 
doubling times (inversely proportional to proliferation rates). Through correlation analyses, we 
found no association between doubling time and centriole number (Spearman correlation 
coefficient: 0.18 (p: n.s.) and 0.2 (p: n.s.) for percentage of cells with CA and mean of centriole 
number, respectively; Figure 4.14a), but a positive correlation with both the percentage of cells 
with COE and the mean of centriole length (Spearman correlation coefficient: 0.28 (p < 0.05) 
and 0.4 (p < 0.01), respectively; Figure 4.14b). In summary, cancer cell lines with overly-long 
centrioles showed lower proliferation rates. 
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Figure 4.14 Cancer cell lines with overly-long centrioles had lower proliferation rates. Relation 
between cell line doubling time (hours) and (a) percentage of cells with CA, (b) mean of centriole 
number, (c) percentage of cells with COE or (d) mean of centriole length (nm), for NCI-60 cancer cell 
lines (Spearman correlation coefficient: 0.18 (p: n.s.), 0.2 (p: n.s.), 0.28 (p < 0.05) and 0.4 (p < 0.01), 
respectively). Grey shades around linear regression lines as in Figure 4.7a. Higher doubling time 
means lower proliferation rate. 
With this result in mind, we wondered how is the cell cycle time associated with centriole 
length? Is this association specific of a particular cell division phase? To answer these 
questions, we used the FACS data provided by O’Connor et al., 1997, where, for each cell line, 
the percentages of cells in each of the G1, S and G2/M phases were estimated. We then 
analysed the correlation between those cell proportions and both the centriole length metrics. 
Overall, we observed a positive correlation with the percentage of cells in G1 phase (Spearman 
correlation coefficient: 0.28 (p < 0.05) and 0.26 (p: n.s.), for percentage of cells with COE and 
mean of centriole length, respectively; Figure 4.15a,b), whereas no association was found for 
the other phases (Figure 4.15c-f). Thus, COE was associated with a longer G1. 
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Figure 4.15 Cancer cell lines with overly-long centrioles have more cells in G1. Relation between 
percentage of cells in (a,b) G1, (c,d) S or (e,f) G2/M cell cycle phases and (a,c,e) percentage of cells 
with COE or (b,d,f) mean of centriole length (nm). Spearman correlation coefficient: (a) 0.28 (p < 
0.05), (b) 0.26 (p: n.s.), (c) -0.19 (p: n.s.), (d) -0.23 (p: n.s.), (e) -0.14 (p: n.s.) and (f) -0.13 (p: n.s.). 
Grey shades around linear regression lines as in Figure 4.7a. 
Correlation does not mean causation, so we then hypothesized that centriole length 
defects may cause a cell cycle delay in G1, which would be expected to be stronger for cells 
that still have an intact p53 response. To test this hypothesis, we compared the correlation 
between centriole length metrics and the percentage of cells in G1 across cell lines with wild-
type (WT) and mutated (MT) TP53. However, we did not find statistically significant different 
associations between TP53 statuses (ANCOVA p: n.s. for both metrics; Figure 4.16).  
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Figure 4.16 TP53 status was not associated with the relation between centriole length defects and 
cell cycle delay in G1. Relation between percentage of cells in G1 phase and (a) percentage of cells 
with COE and (b) mean of centriole length, according to TP53 status (WT: wild-type, MT: mutated; 
ANCOVA test p: n.s. for both). The grey/blue shades around the grey/blue linear regression lines 
represent their 95% confidence intervals for WT/MT. 
4.2.2 PRKACA is a putative promoter of COE in cancer 
In order to identify putative centriole length regulators, we performed correlation 
analyses between gene and protein expression levels of centrosomal genes, retrieved from the 
CentrosomeDB - Centrosomal Proteins Database (Alves-Cruzeiro et al., 2014; Nogales-
Cadenas et al., 2009), and the two centriole length metrics, in the NCI-60 panel. From the 870 
centrosomal genes tested, we identified only one gene significantly correlated with the mean 
of centriole length, whereas none was associated with the percentage of cells with COE (FDR-
adjusted p-value lower than 0.05). Regarding protein expression, we did not find any protein 
significantly correlated with any of the centriole length metrics (FDR-adjusted p-value lower 
than 0.05). However, we also did not find any significant association between centriole length 
and CPAP gene and protein levels, or CP110 gene expression levels (no protein data available), 
two known centriole length regulators (Schmidt et al., 2009), suggesting that centriole length 
dysregulation in cancer could be associated with different mechanisms. 
The candidate identified in these analyses as being associated with centriole length in 
cancer was PRKACA. This gene encodes one of the catalytic subunits of protein kinase A 
(PKA), a family of kinases that phosphorylate many substrates in the cytoplasm and the nucleus 
and whose activity is dependent on cellular levels of cyclic AMP (cAMP; Skålhegg and 
Tasken, 2000). PKA was found to localize at the centrosome (Nigg et al., 1985) and its higher 
activation is associated with increased primary cilium length in mammalian cells 
(Besschetnova et al., 2010). However, there is no previous information about a possible 
relationship between this kinase, or even this specific gene, and centriole length regulation. In 
the NCI-60 panel, PRKACA was positively correlated with the mean of centriole length 
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(Spearman correlation coefficient: 0.58, p < 0.0001; Figure 4.17a), suggesting that higher 
expression of this gene is also associated with increased centriole length in cancer. Regarding 
protein expression, correlation with centriole length was not so significant (Spearman 
correlation coefficient: 0.27, p: 0.07; Figure 4.17b). 
Figure 4.17 PRKACA gene expression levels were positively correlated with centriole length. 
Relation between PRKACA (a) gene or (b) protein expression levels and mean of centriole length (nm; 
Spearman correlation coefficient: 0.58 (p < 0.0001) and 0.27 (p: 0.07), respectively). Grey 
shades around linear regression lines as in Figure 4.7a. 
To further explore the potential role of PRKACA in centriole length, we took advantage 
of an independent screen for putative centriole length regulators, done in Dr Mónica 
Bettencourt-Dias’ lab (unpublished data), where this gene was already tested. Here, PRKACA 
was knocked down using two different siRNAs and then CEP135 and centrin protein intensity 
levels were measured as readouts for centriole length. Indeed, in one siRNA experiment, 
PRKACA knock down was found to significantly decrease centrin protein levels (-2.27 robust 
z-score against the control; t-test p < 0.05), while no significant change was observed in
CEP135 intensity (siRNA-1 on Figure 4.18), highlighting PRKACA as a putative promoter of 
COE in cancer. However, the second experiment (siRNA-2 on Figure 4.18) did not show any 
significant changes in both markers. 
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Figure 4.18 PRKACA knock down decreased centriole length. a) PRKACA expression levels were 
knocked down using two different siRNAs (siRNA-1 and siRNA-2), followed by CEP135 (red) and 
centrin (green) protein intensity levels measurement. siRNA-1 (black) was found to significantly 
decrease centrin intensity levels (-2.27 robust z-score against the control; t-test p < 0.05), but not 
CEP135 intensity (t-test p: n.s.). In turn, siRNA-2 (grey) did not affect centriole length (t-test p: n.s. for 
both CEP135 and centrin changes). b) Depletion of PRKACA led to shorter centrioles in the siRNA-1 
experiment. 
4.2.2.1 Increased centriole length is associated with higher interaction with ECM and 
lower efficiency in DNA repair 
Since we did not observe strong transcriptional changes associated with centriole length 
abnormalities at the level of individual genes, we performed GSEA to identify gene sets 
putatively associated with centriole length abnormalities in cancer. 
In the present work, GSEA results on the transcriptomic changes associated with both 
centriole length metrics could be confounded with the cell line doubling time associated ones, 
since they are positively correlated across the NCI-60 cell lines (Figure 4.14c,d). Therefore, 
for each length metric, we used multiple linear regression models to decouple the effects of 
length and doubling time (explanatory variables) on gene expression and determine which 
genes are independently associated with each length metric. Afterwards, the new lists of genes 
associated with those two metrics (ranked by the moderated t-statistic for differential 
expression) were used in GSEA (Figure 4.19). 
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Figure 4.19 KEGG pathways associated with centriole length abnormalities in cancer. GSEA 
results on the transcriptomic changes associated with (a) percentage of cells with COE and (b) mean of 
centriole length. Pathways positively (red) and negatively (blue) enriched, with a FDR lower than 5%, 
are shown. 
GSEA identified three KEGG pathways enriched in genes positively correlated with the 
percentage of cells with COE levels: amino sugar and nucleotide sugar metabolism, lysosome 
and RNA polymerase (Figure 4.19a). Furthermore, GSEA on the transcriptomic changes 
associated with the mean of centriole length (Figure 4.19b) identified ECM (extracellular 
matrix) receptor interaction and focal adhesion (a type of adhesive contact between the cell and 
ECM) pathways (Figure 4.20a) as positively associated with centriole length, whereas multiple 
pathways related with the ribosome, cell metabolism (retinol, xenobiotics, drugs, nitrogen and 
linoleic) and DNA repair (DNA replication and mismatch repair; Figure 4.20b) were found 
enriched in genes negatively correlated with centriole length. 
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Figure 4.20 Examples of KEGG pathways associated with the mean of centriole length in cancer. 
Enrichment plots of pre-selected pathways (a) positively (ECM receptor interaction (NES: 1.92, FDR 
< 0.05) and focal adhesion (NES: 1.89, FDR < 0.05)) and (b) negatively (DNA replication (NES: -1.97, 
FDR < 0.01) and mismatch repair (NES: -1.8, FDR < 0.05)) enriched in genes overexpressed in cell 
lines with overly-long centrioles (GSEA enrichment plot explained in Materials and Methods, section 
3.2.2).  
4.2.3 Cancer cells with less proteasome activity are more susceptible to CA 
Similarly to centriole length analyses, we performed correlation analyses between 
centriole number abnormality metrics and the 870 centrosomal genes, at both gene and protein 
level. From these analyses, we did not find any gene significantly correlated with any of the 
centriole number metrics (FDR-adjusted p-value lower than 0.05). At the protein expression 
level, one was significantly correlated with the mean of centriole number (FDR-adjusted p-
value lower than 0.05). Yet, we also did not find any significant association with PLK4 (protein 
levels were not available), STIL and SAS-6 gene and protein levels in this panel.  
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The identified candidate was protein PSMD1, whose expression levels were negatively 
correlated with centriole number (Spearman correlation coefficient: -0.53, p < 0.0001; Figure 
4.21). This result suggests this protein as putatively protecting cells from CA. Since we did not 
find this gene’s transcript levels to vary with centriole number, PSMD1 regulation in cancer is 
proposed to be post-transcriptional. This protein is part of the proteasome complex and is 
responsible for substrate recognition and binding (Coux et al., 1996). 
Figure 4.21 PSMD1 protein levels were negatively correlated with centriole number (Spearman 
correlation coefficient: -0.53, p < 0.0001). Grey shades around linear regression lines as in Figure 4.7a.
We then performed genome-wide correlation analyses between gene expression and 
centriole number metrics, followed by GSEA (using the Spearman correlation coefficient to 
rank genes), to identify pathways putatively associated with centriole number abnormalities in 
cancer. We did not identify any pathway significantly associated with the percentage of cells 
with CA at a FDR lower than 5%. 
Interestingly, beyond the previous identification of the PSMD1 proteasome component, 
GSEA also identified the proteasome pathway as enriched in genes negatively correlated with 
the mean of centriole number (NES: -2.25, FDR < 0.001; Figure 4.22a). Proteasomes are large 
protein complexes involved in many essential cellular functions that degrade ubiquitinated 
proteins by an ATP-dependent mechanism. The most common form used in mammals is the 
cytosolic 26S proteasome that contains one 20S protein subunit and two 19S regulatory cap 
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subunits (Coux et al., 1996). Most of the 26S component genes contributed to the proteasome 
negative enrichment result (Figure 4.22b). 
Figure 4.22 Lower expression of proteasome components was associated with increased centriole 
number levels. a) GSEA results on the mean of centriole number-associated transcriptomic alterations 
in the NCI-60 panel. KEGG pathways positively (red) and negatively (blue) enriched respectively in 
genes over- and underexpressed in cell lines with higher centriole numbers, with a FDR lower than 5%, 
are shown. b) The proteasome pathway was enriched in the negatively associated genes (NES: -2.25, 
FDR < 0.001). Genes that contributed the most for that enrichment are highlighted (orange box). GSEA 
enrichment plot explained in Materials and Methods, section 3.2.2. c) Representation of the 26S 
proteasome structure, as well as its 19S and 20S subunits (adapted from Dahlmann, 2005). 26S 
component genes that contributed to the proteasome negative enrichment result are highlighted (orange 
star), including the PSMD1 component (arrow). 
GSEA also identified blood-related pathways (primary immunodeficiency and antigen 
processing and presentation) as being associated with increased centriole number (Figure 
4.22a), most likely due to the observed higher CA levels in blood cell lines (Figure 4.1a). 
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4.3 Identification of new compounds that target CA 
To explore the CA therapeutic potential in cancer, we took advantage of the compound 
activity data available in the NCI-60 panel. We combined these data with the CA profiles 
uncovered for the panel to both understand the general role of CA in cell lines’ compound 
sensitivity and identify new compounds that putatively kill cancer cells through CA. The last 
aim was approached in two different ways: correlation analyses between compound activity 
and both CA levels and expression levels of CA-associated genes. 
4.3.1 CA is associated with higher sensitivity to compound activity 
CA is a common feature in cancer but it is still unknown if it generally confers sensitivity 
or resistance to anti-cancer therapies. To address this question, we performed global Spearman 
correlation between the activity of each of 14,005 compounds and the prevalence of CA (given 
by the percentage of cells with CA) in NCI-60 cell lines. If there was no particular association, 
we expected most correlations to be around zero and similar proportions between positive and 
negative correlations (Figure 4.23 - Expected). However, we observed a statistically significant 
higher proportion of positive correlations (60%, Chi-squared goodness of fit test p < 0.0001; 
Figure 4.23 - Observed), meaning that cell lines with higher CA levels likely tend to have 
higher sensitivity to compound activity. Wherever this is a causal relationship, i.e. CA confers 
higher sensitivity to drug activity, or CA just emerges as a surrogate for other factors needs to 
be experimentally tested.  
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Figure 4.23 Enrichment of positive correlations between compound activity and centrosome 
amplification prevalence. Expected (grey, resulting from 1000 drug activity permutations) and 
observed (blue) density distributions of Spearman correlation coefficients between activity of each of 
14,005 compounds and the percentage of cells with CA across the NCI-60 panel of cell lines. According 
with the expected distribution, positive and negative correlations should present similar proportions: 
50% (Chi-squared goodness of fit test p: n.s.). However, we observed a significant higher proportion of 
positive correlations: 60% (Chi-squared goodness of fit test p < 0.0001). Vertical dashed lines represent 
the mean of each Spearman correlation coefficient distribution. 
4.3.2 Compounds that selectively kill cancer cells with CA 
Since we observed that CA was associated with higher sensitivity to compound activity 
in the panel, we exploited the above-mentioned global Spearman correlation analyses to 
prioritize candidate compounds that selectively kill cancer cells with higher incidence of this 
abnormality. Unfortunately, we did not find any compound positively correlated with the 
percentage of cells with CA at a FDR lower than 5%, i.e. with statistically significant higher 
activity in cell lines that have higher incidence of this abnormality. Nevertheless, the ten 
compounds with the most significant positive correlations (Table 4.1) were selected for further 
in vitro experimental tests, in order to test their CA-selectivity. Compound NSC 633109 
showed the strongest association between its activity and the percentage of cells with CA 
(Spearman correlation coefficient: 0.6, p < 0.001; Figure 4.24). 
Table 4.1 Compounds that have higher activity in cell lines with higher incidence of centrosome 
amplification. Table with the ten compounds with the most significant positive correlations between 
their activity and percentage of cells with CA across NCI-60 cell lines, ordered by nominal p-value. 
NSC ID is the US National Cancer Institute internal ID number and PubChem SID is the PubChem 
substance identifier. The compound with the strongest positive correlation is highlighted (blue box) 
and depicted in Figure 4.24. 
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Figure 4.24 Correlation between activity of top compound NSC 633109 (z score) and percentage 
of cells with centrosome amplification (Spearman correlation coefficient: 0.6, p < 0.001). Grey shades 
around linear regression lines as in Figure 4.7a. The compound’s chemical structure is shown above. 
4.3.3 Compounds that target CA-associated proteins 
An additional way of exploiting CA in cancer therapy would be through the selective 
targeting of proteins that promote supernumerary centrosomes (as discussed in Holland and 
Cleveland, 2014, regarding the targeting of PLK4). To explore this approach, we performed 
correlation analyses between cell line sensitivity for each of the 14,405 compounds and 
expression levels of the gene associated with the main CA-associated protein – PLK4 – across 
NCI-60 cell lines. We used gene expression because protein levels were not available for this 
kinase. The rationale was that compounds inhibiting a specific protein are expected to have 
higher activity in cell lines highly expressing that protein. We did not identify any compound 
with activity positively correlated with PLK4 expression, taking a FDR-corrected p-value 
lower than 0.05. Still, these analyses were used to prioritize the ten compounds with the most 
significant positive correlations (Table 4.2), whose CA-selectivity will be tested 
experimentally using in vitro assays. Compound NSC 658364 showed the strongest association 
between its activity and PLK4 expression levels (Spearman correlation coefficient: 0.62, p < 
0.0001; Figure 4.25). This analysis represents the proof of concept for this approach, which 
could be applied with hereafter identified CA-associated proteins and different datasets 
containing both compound activity and gene and protein expression data. 
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Table 4.2 Compounds that target the centrosome amplification-associated protein PLK4. Table 
with the ten compounds with the most significant positive correlations between their activity and PLK4 
expression across NCI-60 cell lines, ordered by nominal p-value. NSC ID and PubChem SID 
explained in Table 4.1. The compound with the strongest positive correlation is highlighted (blue
box) and illustrated in Figure 4.25.
Figure 4.25 Correlation between activity of top compound NSC 658364 (z score) and PLK4 
transcript levels (Spearman correlation coefficient: 0.62, p < 0.0001). Grey shades around 
linear regression lines as in Figure 4.7a. The compound’s chemical structure is shown above. 
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CHAPTER 5 – DISCUSSION 
Previous studies have demonstrated the importance of centriole number dysregulation in 
cancer, both as a promotor of tumourigenesis (Basto et al., 2008; Coelho et al., 2015; Levine 
et al., 2017; Serçin et al., 2015) and an appealing target for anti-cancer therapies (Mason et al., 
2014; Watts et al., 2013). Moreover, the Bettencourt-Dias Lab have identified COE as a 
recurrent feature of cancer cells that also promotes CA (Marteil et al., manuscript in 
preparation). However, the prevalence and the molecular mechanisms underlying these 
centriole abnormalities in cancer, as well as their therapeutic value, remain poorly understood, 
preventing their use in the clinic. 
We present an innovative and multidisciplinary approach for studying centriole 
abnormalities in cancer that has provided further insights into their associated molecular 
mechanisms and the development of clinical applications based on selectively targeting these 
Achilles’ heels of cancer cells. 
5.1 NCI-60 profile of centriole abnormalities 
Our analyses at the cell population level confirmed CA and COE as widespread 
phenomena among different cancer cell lines and cancer types, where dysregulation in number 
was more common than that in length. However, we recognize two fundamental problems with 
this centriole screen that prevent reaching stronger conclusions about the prevalence of 
centriole abnormalities in cancer. First, the reduced number of profiled cells for each cell line 
does not allow us to accurately estimate their abnormality levels. For instance, with a minimum 
sample of 50 cells and CA observed in eight of them (close to the panel mean of 17%), the 
95% confidence interval for the CA frequency estimate ranges from 7.6% to 29.7%, which 
means a great deal of uncertainty in our estimates of CA prevalence in many cell lines. Second, 
the lack of negative controls does not allow us to define the variability of centriole number and 
length in non-cancerous cell lines, thus limiting the comparison between cancerous and non-
cancerous centriole abnormality profiles. To overcome these issues, the Bettencourt-Dias Lab 
are now increasing the sample size per cell line, as well as performing additional tests in non-
cancerous cell lines. 
We took advantage of the single-centriole resolution of the NCI-60 screen to perform the 
first profiling of abnormalities in individual centrioles in cancer. We observed centriole number 
variability across cell lines from different tissues of origin, with colon and lung being those 
with most heterogeneous ones. Surprisingly, all tissues presented more cells with eight than 
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with seven centrioles. Three possible explanations for this observation: i) cancer cells live more 
stably with eight centrioles, twice the normal number; ii) most cancer cells with eight centrioles 
are a result of cell cycle defects (e.g. cytokinesis failure, mitotic slippage and cell–cell fusion) 
and have accumulated the centrioles from the two expected daughter cells, resulting in twice 
the number expected for an individual cell; iii) some cancer cells with eight centrioles are 
indeed two cells but were detected as being one due to technical issues. Although all three 
causes seem plausible, the technical one is unlikely, given that all microscopy pictures analysed 
in the screen were manually curated, and cell cycle defects are most likely, since they were 
already observed to be a cause of CA (Godinho and Pellman, 2014). 
Similarly, we observed variability at centriole length level across cell lines from different 
cancer tissues of origin, where lung and skin constituted those from which cell lines with higher 
heterogeneity were derived. Interestingly, even within these two tissues of origin there were 
big discrepancies in length variability across cell lines. Particularly, cell line MDA-MB-435 
showed significantly higher length heterogeneity, when compared with other skin cancer cell 
lines, that could be explained by the curious origin of this cell line: it was originally described 
as a human breast cancer cell line, since it was derived from the pleural effusion of a patient 
with breast cancer, but its subsequent molecular characterization (transcript and protein 
expression and drug sensitivity) was consistent with a melanoma origin (Ross et al., 2000; 
Scherf et al., 2000). Furthermore, single nucleotide polymorphism analysis revealed that 
MDA-MB-435 is actually derived from the same individual as the melanoma cell line M14 
(Garraway et al., 2005; Rae et al., 2007). The panel designation for this cell line is still a topic 
of discussion (Chambers, 2009). Nevertheless, given the controversial origin of MDA-MB-
435, it is interesting that it stood out in the NCI-60 panel as that with the highest penetrance of 
COE in the panel. 
CA was found to be associated with particularly aggressive breast (basal) and colon (CIN) 
cancer molecular subtypes in the NCI-60 panel, both characterized by poor prognosis 
(Kocarnik et al., 2015; Parker et al., 2009; Phipps et al., 2015; Sørlie et al., 2001). Breast cancer 
findings were further validated in human tissue samples, in Dr Joana Paredes’ lab (Marteil et 
al., manuscript in preparation). The higher prevalence of CA in these molecular subtypes is 
likely explained by their specific molecular features, such as increased incidence of BRCA1 
mutations in basal-like breast carcinomas (Foulkes et al., 2003), shown to induce centrosome 
overduplication (Ko et al., 2006; Starita et al., 2004), and observed amplification of the Aurora-
A gene in CIN colon cancer (Grady, 2004), whose overexpression leads to supernumerary 
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centrosomes (Ghadimi et al., 2000; Lentini et al., 2007; Meraldi et al., 2002). Altogether, these 
results support the tumourigenic potential of CA in cancer (Chan, 2011). 
We validated the association between COE and CA in the panel both at the cell population 
level, where COE was positively correlated with CA, and at the single-centriole level, where 
we observed higher proportion of overly-long centrioles in cells with CA. However, we were 
not able to establish a causal association and corroborate the previous finding of COE as 
promoter of CA in vitro (Marteil et al., manuscript in preparation). Actually, the existence of 
cell lines with high levels of CA but reduced COE, contrasting with the absence of cell lines 
with high COE but low CA, suggests that CA is necessary for cell lines to develop COE. 
Nevertheless, both hypotheses are compatible: CA can prompt COE, which in turn can promote 
CA by both centriole fragmentation and ectopic procentriole formation (Figure 5.1). This 
positive feedback hypothesis should be tested in the future, in order to better understand the 
association between both types of centriole abnormality. 
Figure 5.1 Hypothesized portrait of the COE-CA association in cancer. COE was shown to promote 
CA both by centriole fragmentation and ectopic procentriole formation. However, our results in the 
NCI-60 panel were also compatible with a positive feedback hypothesis where CA also promotes COE. 
Nevertheless, this hypothesis requires further experimental validation, given that there is no previous 
evidence suggesting CA as a driver of COE. Moreover, our analyses suggest COE as a cell-state 
dependent feature, i.e. specific physiological conditions may be enhancing COE. Hypothesized 
associations are shown in dashed lines (adapted from Marteil et al., manuscript in preparation). 
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Although COE had low frequency in the NCI-60 panel, our results showed that it was not 
a purely stochastic event in cancer cells and it occurred more frequently within the same cell 
than expected by chance, both in cells with or without CA, thus suggesting COE as a widely 
cell state-dependent feature (Figure 5.1), i.e. specific physiological conditions may be 
enhancing COE. Better understanding of the underlying mechanisms would provide novel 
insights in centriolar biology. 
Beyond centriole number and length dysregulation, we found that cancer cells apparently 
do not control their centriolar mass, since the average total centriolar mass increased 
monotonically with the average number of centrioles per cell. In addition, we observed that the 
average centriole length was maintained in cells with supernumerary centrosomes. Thus, there 
was no evidence that any CA arose from centriole fragmentation in the NCI-60 panel. 
However, there are two limitations that prevent us from dismissing this hypothesis: i) 
microscopy resolution was not enough for the detection of centriole shortening; ii) short 
centriole fragments then generally grow until they reach normal length. Nevertheless, we must 
consider the possibility that CA did not arise from centriole fragmentation and other molecular 
mechanisms may be causing number dysregulation in this panel. 
5.2 Novel molecular mechanisms underlying centriole abnormalities in cancer 
The second aim of this project was to explore the molecular origins of both CA and COE 
in cancer by integrating the quantitative centriole profiles along NCI-60 cell lines with the 
publicly available molecular data for the panel. 
Regarding centriole length dysregulation, we identified for the first time an association 
between centriole length and cell cycle progression. We found that cancer cell lines with 
overly-long centrioles proliferated slower and showed an accumulation of cells in G1 phase, 
suggesting that centriole length defects could lead to a cell cycle delay in G1. If this was the 
case, one would expect a stronger association for cells that still have an intact p53 response 
than for those with mutated TP53. However, we did not find a significant difference in the 
relation between centriole length defects and cell cycle delay in G1 between TP53 statuses. 
Although we did not validate this p53-dependent hypothesis in the NCI-60 panel, it would be 
worth to experimentally test the association between centriole length, cell cycle progression 
and the accumulation of cells in G1 phase, given that other p53-independent G1 checkpoint 
pathways could be involved in this process. 
Our transcriptomic analysis identified PRKACA as a putative promoter of COE in cancer 
(Figure 5.2). Among the 870 centrosomal genes tested, only PRKACA expression levels were 
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significantly correlated with centriole length mean. Neither CPAP nor CP110, two known 
centriole length regulators (Schmidt et al., 2009), had their expression significantly correlated 
with centriole length in the panel, suggesting that centriole length dysregulation could be 
associated with different molecular mechanisms.  
PRKACA encodes one of the catalytic subunits of PKA, a family of cAMP-dependent 
serine/threonine kinases that in their inactive form consist of two catalytic (C) and two 
regulatory (R) subunits. Upon binding of cAMP to R subunits, C subunits are released and 
phosphorylate many substrates in the cytoplasm and the nucleus (Skålhegg and Tasken, 2000). 
PKA is mainly docked at the centrosome (Nigg et al., 1985), a process dependent on the A-
kinase anchoring proteins pericentrin and AKAP9 (Grady, 2004), and it is involved in cell 
growth, differentiation, and proliferation, as well as in cell cycle control (Duncan et al., 2006; 
Eyers et al., 2005; Kovo et al., 2006). Particularly, higher PKA activation was associated with 
increased primary cilium length in mammalian cells (Besschetnova et al., 2010). However, to 
our knowledge there are no reports on a possible relationship between that kinase and centriole 
length regulation. 
PRKACA was previously tested in an independent screen for putative centriole length 
regulators, where its depletion led to shorter centrioles in one of two siRNA experiments. The 
other experiment did not yield any difference in centriole length. The screen involved a large-
scale analysis in which the efficiency of depletion was not checked and thus the false negative 
could not be controlled for, which could explain the discrepancy between the outcomes of the 
two siRNA experiments. Therefore, the putative role of PRKACA in the regulation of centriole 
length requires further experimental validation. To validate PRKACA as a centriole length 
regulator, we are planning to first validate PRKACA upregulation in cell lines with overly-long 
centrioles, and then determine the effects of PRKACA up- and downregulation on centriole 
length in cell lines. These analyses will be performed in close collaboration with the 
Bettencourt-Dias Lab. 
We then performed GSEA on the genome-wide COE-associated transcriptomic changes 
to explore the molecular mechanisms associated with centriole length abnormalities in cancer. 
Strikingly, we identified pathways involved in the interaction between the cell and the ECM 
(ECM receptor interaction and focal adhesion) positively associated with COE. Marteil and 
co-workers have shown that overly-long centrioles generate over-active centrosomes that 
nucleate more microtubules (Marteil et al., manuscript in preparation), a known cause of 
invasiveness, but this relationship between overly-long centrioles and cell invasion is not 
established yet. Here we have shown that cell lines with overly-long centrioles presented higher 
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expression of genes involved in the interaction with the ECM, thus providing some new 
insights into a possible effect of overly-long centrioles in cancer cell migration (Figure 5.2). 
The identification of genes involved in DNA repair mechanisms (DNA replication and 
mismatch repair pathways) as negatively associated with centriole length also suggests that a 
drop in efficiency of those mechanisms may allow the presence of overly-long centrioles in the 
NCI-60 cell lines (Figure 5.2). The pathways identified in GSEA need to be properly tested in 
order to establish a causal link with COE, as well as to identify its underlying molecular 
mechanisms. 
Figure 5.2 Hypothesis of centriole over-elongation origins and consequences in the NCI-60 panel. 
We identified PRKACA and lower expression of DNA repair genes as putative promoters of COE in 
cancer. On the other hand, Marteil and co-workers have shown that overly-long centrioles have 
increased microtubule nucleation capacity. Our GSEA results showed an association between COE and 
higher interaction with the ECM, that we hypothesize to be an indirect consequence through higher 
microtubule nucleation capacity. However, a microtubule-independent hypothesis should also be 
considered. Hypothesized associations are shown in dashed lines (adapted from Marteil et al., 
manuscript in preparation). 
In similar genome-wide analyses, we did not identify any strong individual association 
of centriole number with known centriole biogenesis regulators: PLK4 (gene expression level), 
STIL (gene and protein) and SASS6 (gene and protein). This could suggest that centriole 
number dysregulation in cancer is associated with different molecular mechanisms that need 
to be explored. Indeed, we found a strong negative association between the proteasome and 
CA, an unprecedented observation in cancer research. Several genes that encode for 
proteasome components were negatively associated with centriole number, namely PSMD1. 
71 
The 26S proteasome, the form most commonly used in mammals, is a large multisubunit 
enzyme complex present both in the nucleus and cytoplasm of all eukaryotic cells that primarily 
degrades proteins in a ATP/ubiquitin-dependent process (Adams, 2003). It is composed by one 
20S protein subunit and two 19S regulatory cap subunits (Coux et al., 1996). PSMD1 encodes 
for the largest non-ATPase subunit of the 19S regulator proteasome lid, responsible for 
substrate recognition and binding, and its individual protein levels were negatively correlated 
with centriole number. 
Proteasomes regulate the turnover of numerous cellular proteins involved in essential 
cellular processes, such as cell-cycle progression and apoptosis (Adams, 2003; Livneh et al., 
2016). Remarkably, proteasomes have been shown to localize to centrosomes (Wigley et al., 
1999), where they play a critical role in regulating centrosomal proteins, hence maintaining 
proper centrosome function (Didier et al., 2008). For instance, proteasome inhibition resulted 
in a significant increase in centrosome size (Adams, 2003), putatively due to an accumulation 
of different centrosome proteins (Didier et al., 2008). Moreover, all the members of the PLK4–
STIL–SAS-6 module were shown to be regulated through proteasome-mediated degradation 
(Arquint and Nigg, 2014; Cunha-Ferreira et al., 2009; Strnad et al., 2007) and proteasome 
inhibition was shown to induce CA in Drosophila (Cunha-Ferreira et al., 2009), highlighting 
the relevance of proteasome in preventing centriole number abnormalities. 
Although a negative association between the proteasome and CA has been previously 
established in Drosophila, there is no evidence that it can happen in cancer per se. Therefore, 
the proteasome-CA negative association observed in the NCI-60 panel provides a remarkable 
insight into the putative molecular mechanisms driving CA in cancer. Together with previous 
knowledge from literature, this result led us to hypothesize that NCI-60 cell lines that present 
lower expression of proteasome machinery genes, i.e. putative lower proteasome activity, can 
also have higher levels of PLK4–STIL–SAS-6 module proteins (and possibly other 
centrosomal proteins), due to lower protein degradation, driving the observed higher CA levels 
(Figure 5.3). Thus, proteasome is proposed to protect cells from CA, meaning that cells with 
less proteasome activity would be more susceptible to exhibit supernumerary centrosomes 
susceptible of conferring advantage and consequent higher tumourigenic potential to those 
cells. 
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Figure 5.3 Hypothesis of centrosome amplification origin in the NCI-60 panel. Our results identify 
the proteasome as a putative protector of cells from CA. Since the proteasome is known to regulate 
several centrosomal proteins at the centrosome, including the PLK4–STIL–SAS-6 module components 
crucial in centriole biogenesis, we hypothesize that NCI-60 cancer cells present CA levels due to 
reduced proteasome activity and consequent PLK4, STIL and SAS-6 accumulation. Hypothesized 
associations are shown in dashed lines (adapted from Marteil et al., manuscript in preparation). 
Although our correlation analyses in the NCI-60 panel did not identify any correlation 
between centriole number and individual STIL or SAS-6 protein levels, we were not able to 
test the association with all the PLK4–STIL–SAS-6 module components, since there were no 
PLK4 protein levels available for this panel, PLK4 being the master regulator of centriole 
biogenesis. Therefore, this hypothesis needs to be properly experimentally tested. Indeed, we 
are already planning those experiments, in collaboration with the Bettencourt-Dias Lab, testing 
if proteasome inhibition induces CA in cancer cell lines, where we will also assess the 
respective PLK4, STIL and SAS-6 protein levels. 
5.3 Therapeutic value of CA in cancer 
One main advantage of the NCI-60 panel is its large database of anticancer drug activity. 
We have used these data on cell line sensitivity in order to both investigate the CA therapeutic 
potential in cancer and identify novel compounds that target this abnormality. 
Our results disclosed CA as generally associated with higher sensitivity to compound 
activity. However, since CA could have emerged as a surrogate for other factors, e.g. genomic 
instability, this direct association needs to be experimentally tested. The validation of this 
hypothesis will highlight the CA therapeutic potential and intensify the search for novel 
targeted compounds.  
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Correlation analyses between compound activity and both CA and PLK4 gene expression 
levels did not uncover significantly associated compounds. Still, these analyses were used to 
prioritize the ten compounds (number of compounds selected based on budget limitations) with 
the most significant positive correlations in both analyses. Their activity will be experimentally 
validated using in vitro models, particularly in NCI-60 cell lines with different CA levels, 
together with non-cancerous cell lines, to test compound CA-selectivity. Compounds that show 
specific targeting of abnormal cell lines, without affecting normal ones, will be selected for 
subsequent studies to validate their centrosome-directed mechanism of action. Furthermore, 
we will apply chemical informatics approaches to pinpoint the common chemical properties 
among the prioritized compounds because we believe this approach will provide new insights 
into the chemical properties that confer their ability to specifically target cells with CA and 
thereby become a powerful tool in drug design and modulation. Moreover, by identifying 
compounds that target CA, we will be able to then explore the molecular mechanisms 
associated with their activity, thus providing novel insights into the CA-associated mechanisms 
in cancer. 
Both chemical informatics approaches and experimental validation of promising 
compounds will be performed in close collaboration with Dr Gonçalo Bernardes’ group 
(Instituto de Medicina Molecular), taking advantage of their strong expertise in chemistry and 
targeted cancer therapeutics. 
Given the cancer-specificity of CA, the compounds identified will be the basis for the 
development of drugs to selectively target cancer cells, hence promising a shift in the way we 
treat this group of diseases. 
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CHAPTER 6 – CONCLUSION 
Altogether, this project has covered different aspects of centriole abnormalities in cancer, 
taking advantage of a unique resource created by the rigorous quantification of centrosome 
structure in a cell line panel also well characterized at the molecular level. Moreover, the 
created resource allows the investigation of additional relevant questions on centriole 
abnormalities in cancer. Indeed, we have already quantified the CC levels in the NCI-60 panel, 
only possible because the centriole screen was performed in mitotic cells, that will now be 
integrated with the publicly available molecular and drug-sensitivity quantitative profiles for 
that panel, to uncover the prevalence, origins and therapeutic value of CC in cancer. 
The first aim of profiling the centriole abnormalities along the panel has provided a first 
glimpse of the landscape of such abnormalities in cancer, described in a manuscript (Marteil et 
al., manuscript in preparation), to be submitted to Nature Communications soon, that also 
includes the NCI-60 centriole screen and the identification of COE as a widespread 
phenomenon in cancer. The second and third aims have raised interesting and putatively 
relevant hypothesis in the centrosome-cancer field that will now be experimentally validated 
in order to better characterize the associated candidate molecular mechanisms and compounds. 
This project was presented by this thesis’ author in two international meetings: poster 
presentation at the 3rd EACR Conference in Cancer Genomics, Cambridge, UK; oral 
presentation at the 12th Young European Scientists meeting, Porto, Portugal, whose abstract 
was published in Porto Biomedical Journal (de Almeida et al., 2017; 
10.1016/j.pbj.2017.07.019). 
To conclude, this work presents the first single-centriole-level portrait of centriole 
abnormalities in cancer and contributes to a better understanding of their origins, namely by 
revealing novel molecular mechanisms in cell cycle biology. We ultimately expect the results 
of our pioneering multidisciplinary approaches to provide novel targeted cancer therapeutic 
options and inspire a new way of studying and handling cancer. 
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ANNEXES 
Annex 1 Table with centriole abnormality metrics for each NCI-60 cell line: percentage of cells 
with CA, mean of centriole number, percentage of cells with COE and mean of centriole length. Cell 
lines whose metrics were calculated from primary screening data are highlighted (blue). 
90 
Annex 2 Correlation plot between cell lines’ doubling time estimated by the U.S. National Cancer 
Institute and calculated on O’Connor et al., 1997 (Spearman correlation coefficient: 0.96, p < 
0.0001). The grey shade around the blue linear regression line represents its 95% confidence interval. 
91 
Annex 3 Distribution of gene expression variance across NCI60 samples. Microarray probes with 
log-intensity variance higher than 1 are not included. Vertical dashed line (log-intensity variance = 0.1) 
represents the quality control criteria used to remove probes whose expression does not vary across 
samples. 
92 
Annex 4 Distribution of protein expression variance across NCI60 samples. Peptides with log-
intensity-based label-free quantification variance higher than 0.5 are not included. Vertical dashed line 
(log-intensity variance = 0.025) represents the quality control criteria used to remove peptides whose 
expression does not vary across samples. 
93 
Annex 5 Distribution of drug activity variance across NCI60 samples. Compounds with log-
intensity variance higher than 1.1 or lower than 0.8 are not included. Vertical dashed line (activity 
variance = 0.99) represents the quality control criteria used to remove compounds whose activity does 
not vary across samples. Drug activity measured in z-transformed negative log10 of GI50. 
94 
Annex 6 Tissue hierarchical clustering based on centriole heterogeneity. Unsupervised 
hierarchical clustering using Euclidean distances calculated based on Fligner-Killeen p-values across 
all combinations of tissue pairs for centriole (a) number and (b) length heterogeneity. Heatmap colour 
scale according with -log10 of Fligner-Killeen p-values: darker blue reflects bigger differences across 
tissue pairs. Main clusters are highlighted with different shades of grey. 
